Camain, R., (A) 274
Cameron, C. H., (A) 478
Candeias, J. A. N., (A) 272
Canos Llácer, I., (A) 142
Cao, E. A., (A) 139
Carayon, A., (A) 274
Cardama, J. E., (A) 471, 484
Cardenas, A. C., (A) 480
Casero, R. A., Jr., (A) 143
Castro Díez, M. C., (A) 281
Catalano, C. J., (A) 126
Cates, C. J., (A) 360
Cellona, R. V., (O) 21, 427
Chacko, C. J. G., (O) 1, (A) 132, 133, 277
Chadda, V. S., (A) 474
Chae, J. R., (A) 376
Chakraborty, A., (A) 468
Chakravarti, R. K., (A) 280, 482
Chakravarty, R. N., (A) 129, 132
Chandor, S. B., (A) 272
Chandra, S., (A) 482
Chao, W. T., (A) 272
Chaparas, S. D., (A) 284
Charles, J., (A) 126
Charosky, C. B., (A) 470, 484, 484
Chase, M. W., (A) 275
Chatenoud, L., (A) 475
Chatterjee, B. R., (A) 137
Chaubey, B. S., (A) 369
Chaudhary, R. C., (A) 375
Chaudhury, S., (A) 362
Chauhan, N. S., (A) 484
Chawla, S. N., (A) 135
Childs, G. E., (A) 143
Choe, J., (A) 369
Choi, S. R., (A) 365
Chopra, J. S., (A) 471
Chou, H., (A) 367
Christian, M., (A) 122, 376
Chulawala, R. G., (O) 398
Chung, S. M., (A) 376
Cinn, Y. W., (A) 361
Clavel, S., (A) 122, 372, 372
Clément, F., (A) 122, 372, 372
Clements, B. H., (B) 115
Closs, O., (C) 85, (A) 138, (O) 147, (A) 375, 477, 477
Clough, J. D., (A) 135, 143
Cochrane, R. G., (E) 67
Cocito, C., (A) 372
Cockburn, R., (A) 120
Cohen, H., (A) 136
Colin, M., (A) 269
Collins, F. M., (O) 180
Colston, M. J., (O) 317, (A) 499
Constable, T. J., (A) 270
Conti, R., (A) 121
Convit, J., (A) 128, 370
Cordes, D. O., (A) 284
Costagliola, G., (A) 470
Cottenot, F., (O) 42, (A) 475
Crawford, C. L., (C) 90
Crockson, A. P., (A) 270
Crockson, R. A., (A) 270
Crovato, F., (A) 377
Curtis, J., (A) 482

Daffé, M., (A) 372
D'Amelio, R., (O) 27
Damle, P. T., (A) 468
Daneshmend, T. K., (A) 361
Danno, K., (A) 144
Darshan, H., (A) 129, 366
Dasgupta, A., (A) 273
Dastur, D. K., (A) 369
Datta, D. V., (A) 126
David, H. L., (A) 122, 372, 372
Davidson. P. T., (A) 468
Davies, P., (A) 270
Davies, R. A., (A) 361
Dayal, S. G., (A) 473
de Bergeyck, E., (A) 122
Debi, B. P., (A) 128
de la Cruz, E. C., (O) 427
Delaney, M. W., (N) 466
del Real Sanchez, J. H., (A) 480
de Mesquita, A. P., (A) 485
de Millian, S. G., (A) 139
de Montaigne, E., (A) 269
de Muynck, A., (A) 122
de Perez Nardini, S., (A) 134
Deresinski, S. C., (A) 378
de Rott, M. I. O., (A) 139
Desikan, K. V., (A) 123, 126, 127, 128, 276, 363, 470, 472
Desjardins, R. E., (A) 143
Desowitz, R. S., (A) 283
Dethlefs, R., (A) 365
Devi, C. S., (C) 344
de Vries, R. R. P., (A) 140
de Wit, M., (A) 361, 468, 469, 469
Dhall, K., (O) 177, (A) 272
Dhar, U., (A) 484
Dhople, A. M., (O) 57, (A) 137, 278, 502
Diamantopoulos, E. J., (A) 130
Discamps, G., (A) 274
Dorfman, M., (A) 131
Draper, P., (A) 135, (O) 147, 287, (A) 371
Dubey, G. K., (A) 369
Duncan, M. E., (A) 133, 471, 471
Dutt, B., (A) 473
Dutta, R. K., (A) 122, 123
Dwivedi, M. P., (A) 141

Edwards, E. A., (A) 483
Eggelte, T., (A) 468, 469
Eikman, D. A., (A) 378
El-Beheiry, A., (A) 271
El-Ghazzawi, E., (A) 271
Ellard, G. A., (A) 123, 269, 469

El-Mansy, E., (A) 271
Esterly, N. B., (A) 487

Fajardo, T. T., (O) 21, 427
Falkinham, J. O., III, (A) 284
Fenske, N. A., (A) 283
Fernandez Baquero, G., (A) 135
Ferracci, C., (C) 91, (A) 268
Ferrando, J., (O) 315
ffytche, T. J., (A) 365, 365
Fieldsteel, A. H., (O) 317, (A) 499
Fine, P. E. M., (E) 437
Fox, W., (A) 483, 487
Fraguela Rangel, J., (A) 135
Freerksen, E., (B) 114
Fregnan, R. C., (A) 363, 364
Frey, H. M., (A) 469
Frimodt-Moller, J., (A) 486
Fritschi, E. P., (A) 376
Fukunishi, Y., (O) 406, (A) 499
Funazu, T., (A) 269

Gabrielli, M., (A) 123, 142, 470
Ganapati, R., (A) 281, 282
Gandagule, V. N., (A) 129
Gangadharam, P. P., (A) 468
Ganguly, N. K., (A) 132, 132, 132, 280, 482
García Basterrechea, J. M., (A) 281
Garcia-Ortigoza, E., (O) 287
Garfield, E., (A) 120
Garg, B. R., (A) 125, 125, 135, 272, 362, 377
Gatner, E. M. S., (A) 360, 360
Gatti, F., (A) 123, 484
Gatti, J. C., (A) 470, 471, 484
Gaulier, A., (A) 477
Gaur, U. C., (O) 37, (A) 363
Gelber, R. H., (A) 139, 514
George, K. L., (A) 284
George, T., (A) 129
Gerone, P. J., (A) 500
Gershon, A. A., (A) 468
Gervasi, V., (A) 127
Geshue-Taylor, G., (E) 64
Gesme, D., (A) 366
Gharpuray, M. B., (A) 472
Gharpuray, S. M., (A) 472
Ghei, S. K., (A) 131
Ghosh, E., (A) 271
Ghosh, S., (A) 362
Ghuysen, J. M., (A) 372
Gibson, J., (A) 144, 144
Gidoh, M., (A) 269
Gilbie, S. G., (A) 377
Gillis, T. P., (C) 88, (O) 287, (A) 504, 506
Gil Minguillón, C., (A) 142
Girdhar, A., (A) 472
Girdhar, B. K., (A) 123, 131, (O) 307, (A) 470, 472, 474
Godal, T., (A) 128
Goncalves, A., (A) 485
Gopinath, T., (A) 130
Gormus, B. J., (A) 500
Govil, D. C., (O) 37, (A) 363, 369
Govilla, A. K., (A) 140, 377
Goyal, B. M., (A) 473
Grabow, G., (A) 360
Grange, J. M., (B) 114, (A) 144, 144, (A) 278, 283
Gratacos, R., (O) 315
Greenwood, D., (A) 468
Gregory, D., (A) 374
Grossman, M. E., (A) 272
Gruft, H., (A) 284
Guha, P. K., (A) 281, 482
Guinto, R. S., (O) 21, 427
Gupta, B. K., (A) 483
Gupta, D. K., (A) 129
Gupta, J. C., (A) 129, 129
Gupta, M. C., (A) 473
Gupta, P. N., (A) 469
Gupta, S. C., (O) 37, (A) 363, 369
Gupta, S. K., (O) 9
Gupte, M. D., (A) 140
Gurnani, S., (A) 130

Haddad, N., (A) 363, 364
Hah, Y. M., (A) 363
Haile, G. S., (A) 468
Hak-Bung, K., (A) 370
Halpern, R., (N) 358
Hameedulla, A., (A) 362
Han, S. H., (A) 370, 476
Handa, F., (O) 311
Hanks, J. H., (O) 57, (A) 137, 278
Harahap, M., (A) 483
Harboe, M., (C) 85, (A) 133, 138, (O) 147, (A) 477
Hardas, U., (A) 369, 370
Hargrave, J. C., (B) 115, (A) 121, 126, 272, 359
Hariparsad, D., (A) 143
Harman, D. J., (O) 167
Harris, E. B., (A) 281, 374
Harris, W. D. M., (A) 284
Hassan, K. M., (A) 512
Hastings, R. C., (E) 73, (N) 109, (A) 123, 125, (N) 460, (A) 463, 464, 468, 478, 510, 512
Hathaway, J. C., (A) 272
Hazra, S., (A) 362
Hébrant, F., (A) 373
Hedrick, J. L., (A) 376
Hernandez Angulo, M. H., (A) 135
Hill-Smith, I., (E) 223
Hitze, K. L., (A) 145
Hoeltge, G. A., (A) 143
Homeida, M., (A) 361
Horio, T., (A) 144
Hu, C. K., (Ob) 84
Hu, S. C., (A) 370, 476
Huikeshoven, H., (E) 228, (A) 361, 468, 469, 469
Humphres, R. C., (A) 512, 514
Hunter, S. W., (A) 504
Hurtrel, B., (A) 374

Husser, J. A., (A) 366
Hymas, P. G., (A) 366

Ichihara, K., (A) 278, 373
Ilfield, D., (A) 144
Imamura, S., (A) 144
Imkamp, F. M. J. H., (O) 159, (A) 360, 470
Ishaque, M., (A) 481
Ito, T., (A) 508
Iyer, C. G. S., (A) 141
Izumi, S., (A) 275, 278, 373

Jacobson, R. R., (A) 475, 510, 515
Jain, A. K., (A) 130
Jakim, I. H., (A) 471
Janczura, E., (A) 372
Janssens, P. G., (A) 122
Jayam, S., (A) 282
Jayaraman, P., (A) 124
Jesudasan, K., (A) 376
Jesudasan, S., (A) 376
Jhala, C. I., (A) 488
Ji, B. H., (A) 274
Jiménez Guillén, J., (A) 281
Job, C. K., (O) 1, (A) 132, 133, 277
Joffe, M., (O) 159
Joglekar, V. K., (A) 369
John, S. P., (A) 376
Jones, E. R., (B) 115
Jones, R. L., (A) 362
Jopling, W. H., (N) 462
Joseph, A., (A) 141
Joseph, M., (O) 1, (A) 277
Joshi, L. D., (A) 473
Jundal, S. K., (C) 94

Kanchana, M. V., (A) 280
Kano, K., (A) 370
Kanwar, A. J., (A) 140
Kaplan, M. H., (A) 275
Kaplan, R., (A) 127
Kardjito, T., (A) 144, 144, 283
Karuga, W. K., (A) 483
Kasbekar, V., (A) 271
Kashiwabara, Y., (A) 372
Kasik, J. E., (A) 269
Kato, L., (C) 93, (A) 481
Katoch, V. M., (A) 131, 481
Katoh, M., (A) 507
Kaur, M., (A) 280, 482
Kaur, P., (A) 281, 482, 482
Kaur, S., (O) 9, (C) 94, (A) 124, 126, 129, 129, 129, 132, 132, 132, (O) 177, (A) 272, 275, 280, 366, 471, 482
Kazda, J. M., (C) 345
Kelkar, S. S., (A) 472
Khamenei, A. A., (A) 277
Khan, P. M., (A) 140
Kim, D. I., (A) 366, 370, 375, 376
Kim, W. I., (A) 369
Kim, W. S., (A) 361
Kirchheimer, W. F., (A) 281, (O) 287, (A) 374
Klayman, D. L., (A) 143
Ko, Y. H., (A) 362, 376
Kohsaka, K., (O) 406, (A) 508
Koide, S., (A) 269
Kok, S., (O) 159, (A) 360
Koshy, A., (A) 126
Koshy, T. S., (O) 31
Kotteeswaran, G., (A) 132
Kouri Flores, J. B., (A) 135
Koya, G., (A) 477
Krahenbuhl, J. L., (A) 512, 514
Krakauer, R. S., (A) 143, 144
Krishna Murthy, K., (A) 124
Krishnaswami, K. V., (A) 487
Krishnaswamy, P. R., (O) 49
Kritzinger, N. A., (A) 269
Kronvall, G., (A) 138
Kumar, B., (O) 9, (C) 94, (A) 124, 126, 129, 129, 129, 132, 132, 132, (O) 177, (A) 272, 275, 280, (O) 294, (A) 366, 471, 482
Kumar, R., (O) 37, (A) 129, 369
Kumar, Y. M., (C) 344
Kundu, S. K., (A) 362
Kuo, S. L., (A) 476
Kuppusamy, P., (A) 141
Kusaka, T., (O) 406, (A) 499
Kushwah, S. S., (A) 140, 377
Kusunose, E., (A) 278, 373
Kusunose, M., (A) 278, 373
Kvach, J. T., (A) 502

Lagrange, H., (A) 374
Laja, A. O., (A) 271
Lal, S., (A) 125, 125, 135, 268, 272, 362, 377
Landheer, J. E., (A) 361, 468, 469, 469
Lanéelle, M. A., (A) 372
Lang, W. R., (A) 130
Launay, J.-M., (O) 42
Lawrence, D. N., (A) 132
Lechat, M. F., (E) 60
Lefford, M. J., (A) 375
Lehrer, A. B., (A) 483
Leiker, D. L., (B) 116, (A) 361, 468, 469, 469
Lele, V., (A) 370
Lenka, M. R., (A) 271
Lesourd, M., (A) 372
Levi, L., (A) 377
Levis, W. R., (A) 376
Levy, L., (A) 138, 362
Leyh-Bouille, M., (A) 372
Liew, F. Y., (A) 478, 479
Linari, S., (A) 142
Lisker, R., (A) 141
Little, P. B., (A) 284
Liturri, M., (A) 127
Liu Jihe, (A) 367
Livshin, Y., (A) 474
Li Wenzhong, (A) 367

Logie, P. S., (A) 375
Lombardi, C., (A) 482
Loo, S. T., (A) 370
López Soriano, F., (A) 281
Løvik, M., (A) 375, 477
Lowe, C., (A) 135, 371
Lu, S.-T., (A) 476
Lydyard, P. M., (A) 273

McAdam, K. P. W. J., (A) 371
McConkey, B., (A) 270
McCray, M. K., (A) 487
McDougall, A. C., (C) 91, (O) 167, (A) 362, (O) 393
Ma Bukuan, (A) 367
Mackey, D. M., (A) 127
Madan, N., (A) 487
Madarang, M. G., (O) 21
Madden, J. A., (A) 378
Madlener, F., (A) 277
Mahadevan, P. R., (A) 124
Ma Haide, (E) 218
Mahajan, R. C., (A) 132
Maheshwari, A., (A) 487
Makonkawkeyoon, S., (A) 515
Malaviya, G. N., (A) 485
Malhotra, S., (O) 177
Malhotra, Y. K., (A) 140
Malik, A. K., (A) 275
Malik, S. K., (C) 94
Malla, O. K., (A) 364, 366
Mani, M. Z., (A) 483
Marchand, J. P., (A) 366
Marshall, J. T., (A) 282
Martin, F. I. R., (A) 473
Martin, G. G., (A) 141
Martin, L., (A) 500
Martinez, A. R., (A) 139
Martinez-Palacios, B. N., (A) 276
Mascaro, J., (O) 315
Mason, L., (A) 515
Mathews, M., (O) 31, (A) 483
Mathias, C., (A) 133
Mathur, D. R., (A) 135
Mathur, N. K., (A) 483
Matsuki, G., (A) 372
Matsumoto, Y., (A) 275
Matsuo, Y., (O) 302, (A) 507
Maydat, L., (A) 274
Meesters, H. J. R., (A) 140
Mehendale, M. S., (B) 266
Mehra, N. K., (A) 134, 140
Mehra, V., (A) 515
Mehta, L., (A) 271
Mehta, N. R., (A) 140
Mehta, R. P., (A) 475
Melchior, E., Jr., (A) 363, 364
Melsom, R., (A) 133, 471
Melvin, I. G., (A) 284
Menezes, S., (A) 270
Mester, L., (O) 42, (A) 124
Mester, M., (O) 42, (A) 124
Meyers, W. M., (A) 500
Milano, C. F., (O) 27
Milgrom, F., (A) 370
Millan, J., (A) 141
Miller, L. H., (A) 283
Miller, R. A., (A) 506
Millns, J. L., (A) 283
Minagawa, F., (A) 503
Miranda, R. O., (A) 138, 478
Misra, R. C., (A) 133
Misra, S. N., (A) 130, 474
Mitra, S. K., (A) 482
Mock, B., (C) 457
Modabber, F. Z., (A) 273, 277
Modderman, E. S. M., (A) 271
Mohamed, F. A., (A) 479
Mohanty, H. C., (A) 128
Moleres Ferrandis, R., (A) 472
Monick, M., (A) 269
Moniz-Pereira, J., (A) 122
Morales, C. R., (A) 139
Morales, M. J., (A) 478
Moreno, E., (A) 273
Mori, T., (A) 508
Morrison, N. E., (O) 180, (A) 510
Moulopoulos, S. D., (A) 130
Mukherjee, A., (A) 131
Muliyil, J., (A) 141
Murray, J. F., Jr., (O) 302
Murray, L. P., (A) 139
Murthy, J. M. K., (A) 471
Myles, K., (A) 473

Naafs, B., (C) 459
Nagai, T., (A) 275
Nahra, M., (A) 141
Naidoo, P., (A) 143
Naik, S. S., (A) 130
Nakagawa, H., (A) 372
Nakamura, M., (A) 278, 279, 502
Nalli, G. A., (A) 282
Narain, R., (A) 284
Narang, A. P. S., (A) 126
Narayana, R. B., (A) 370
Narita, M., (A) 269
Narita, N., (A) 477
Nassau, E., (A) 144
Nath, I., (A) 133, 134, (O) 187, (A) 370
Navalkar, R. G., (A) 134, 280, 280
Navarette, J. I., (A) 141
Neimark, A. E., (B) 117
Nelson, K., (A) 515
Nemati, T., (A) 277
Ness, P. M., (A) 366
Neves, R. G., (A) 363, 364
Ng, H., (A) 138, 139
Ng, Y. Y., (A) 361
Niemer, A. Q. H. J., (A) 469
Nigam, J. P., (A) 129, 473

Nishimaki, T., (A) 370
Nishiura, M., (A) 499
Nordeen, S. K., (A) 128
Nsanzumuhire, H., (A) 483
Nsibambi, J., (O) 16, (A) 473
Nuti, M., (O) 27, (A) 136, 136, 479, 480

Ocampo, J. C., (A) 471
O'Donnell, M. J., (A) 272
Ofuji, S., (A) 144
Okada, S., (A) 499
Omar, M. A. K., (A) 143
O'Neill, S. M., (A) 139
Opromolla, D. V. A., (O) 393
Orihula Calatayud, M. C., (A) 281
Ortiz, S., (A) 368
Ottati, S., (A) 272
Otte, A., (A) 142
Ozawa, T., (A) 503

Pagnano, P. M. G., (A) 363, 364
Palande, D. D., (A) 377
Palmisano, L., (O) 27
Panda, P. K., (A) 129
Pandey, S. S., (A) 281
Pandya, S. S., (A) 281, (O) 398
Paneerselvam, R., (A) 125
Panja, S. K., (A) 271, 488
Pannikar, V. K., (A) 272
Park, E. S., (A) 376
Park, K. W., (A) 376
Park, Y. J., (A) 363
Parker, B. C., (A) 284
Parvez, M., (A) 130, 474
Patra, B. S., (A) 488
Patra, S. B., (A) 488
Patrudu, M., (C) 344
Pattyn, S. R., (A) 125, 125, (O) 194, (A) 268, 373
Paul, S., (C) 342
Pavithran, P., (O) 311
Pearson, D. A., (A) 282
Pearson, J. M. H., (O) 417, (A) 469, 471, 471
Peluso, I., (A) 473
Pennec, J., (O) 42
Pérez-Briceño, R., (A) 141
Perkins, F. T., (A) 128
Perkins, H. A., (A) 366
Peters, J. H., (O) 302
Pettit, J. H. S., (C) 95
Phan Dinh Tuy, F., (A) 475
Pillai, K. K., (A) 486
Pillay, N. L., (A) 143
Piper, L. M., (A) 511
Piva, J. R., (A) 134
Portaels, F., (O) 194, (A) 481
Porwal, G. L., (A) 369
Prabhakaran, K., (A) 281, 374
Pratt, P., (A) 468
Promé, J. C., (A) 372

Qiang Nengxian, (A) 367
Quesada-Pascual, F., (A) 506

Radhakrishna, S., (A) 487
Radhakrishnan, K., (A) 471
Radia, K. B., (O) 383
Radnakrishnan, N., (A) 471, 473
Raj, V., (A) 377
Raja Babu, K. K., (A) 124
Raju, B. D., (A) 367
Ramanujam, K., (O) 1, (A) 277
Ramasekar, K., (A) 282
Ramesh, H. C., (A) 282
Rampure, A. M., (A) 134
Ramu, G., (A) 126, 127, 128, 131, 141, 276, 363, 472
Rangarajan, R., (C) 455
Rao, B. N., (C) 344
Rao, P. R., (A) 473
Rao, S. S. L., (A) 473
Rathore, B. S., (A) 360
Ratnam, A. V., (A) 134
Rea, T. H., (A) 371, 516
Reddy, C. R. R. M., (C) 344
Reddy, S. C., (A) 367
Rée, G. H., (A) 121, 126, 272, 473, 478
Rees, R. J. W., (A) 128, 135, 277, 371, 471, 478, 479
Rege, V. L., (A) 270
Reich, C. V., (O) 21
Reitan, L. J., (O) 147
Resoagli, E. H., (A) 139
Resoagli, J. P., (A) 139
Revankar, C. R., (A) 281
Rial, R. M. L., (A) 474
Ridel, P. R., (C) 91
Ridley, D. S., (A) 371, (O) 383, (A) 471
Ridley, M. J., (A) 371
Robins, K., (A) 130
Rojas-Espinosa, O., (O) 287
Rolston, R., (O) 31
Rook, G. A. W., (A) 273, 276, 276, 277, 478
Rosario, V., (A) 378
Rose, E. T., (C) 342
Rosenfeld, M., (B) 114

Sachdev, K. N., (A) 135
Saint-André, P., (C) 91, (A) 268
Sakamoto, Y., (A) 269
Salama, N., (A) 271
Samuel, N., (A) 277
Sanabria Negrin, J. G., (A) 135
Sansarricq, H., (A) 128
Sarangi, B. K., (A) 128
Sathish, M., (O) 187, (A) 370
Sato, N., (O) 317
Saúl, A., (Ob) 83
Sawhney, B. B., (A) 471
Schauf, V., (A) 515
Scheinberg, M. A., (A) 474
Scovill, J. P., (A) 143
Sehgal, S., (O) 294

SEHGAL, V. N., (A) 270
SEKHAR, K., (A) 282
SELVA, J. S., (A) 484
SELVAPANDIAN, A. J., (A) 141
SEMINARA, R., (O) 27
SENGUPTA, L. K., (A) 488
SENGUPTA, U., (A) 126, 131, 276, 278, 279, 363
SETH, P., (A) 488
SEYDEL, J. K., (C) 90
SHAH, K. C., (A) 488
SHANNON, E. J., (A) 478
SHARDA, D. P., (A) 130
SHARMA, A., (A) 488
SHARMA, S. C., (A) 126, 132, 132, (O) 177, (A) 272, 280, 482
SHEPARD, C. C., (A) 128, 135, 139, 371
SHER, R., (O) 159
SHESHADRI, P. S., (A) 268
SHESKIN, J., (A) 131, 136, (A) 474
SHETTY, K. T., (O) 49
SHETTY, V. P., (O) 324
SHILO, S., (A) 474
SHIN, D. H., (A) 376
SHRINIWAS, (A) 485
SIDHU, K. S., (O) 311
SIMSON, I. W., (O) 159
SINGH, C., (A) 360
SINGH, G., (A) 281, 482, 482
SINGH, R., (A) 133, 370
SINGH, S., (A) 129, 129
SINGHAL, A. L., (A) 474
SINHA, S. N., (O) 37, (A) 276, 363, 369
SIVAMANI, S., (A) 135, 272
SKINSNES, O. K., (Ob) 84, (C) 341
ŠLJIVIC, V. S., (A) 273, 274
SMELT, A. H. M., (A) 478, 479
SMITH, W. C. S., (A) 131
SOETERS, A., (A) 361, 468, 469
SOHN, J. G., (A) 363
SOLOMON, D. A., (A) 378
SOMASUNDARAM, P. R., (A) 487
SONG, J. Y., (A) 376
SOOD, S. K., (A) 487
SORRENTINO, M. C., (A) 142
SOYINKA, F., (A) 271
SPITZ, I. M., (A) 474
SREEVASTA, B. K., (A) 470
SREEVATSA, (A) 123, 363
SRINIVAS, R. V., (A) 488
SRITHARAN, V., (A) 128, (O) 307, (A) 474
SRIVASTAVA, P., (A) 473
SRIVASTAVA, V. K., (A) 485
STANFORD, J. L., (A) 273, 276, 277, 277
STOLZ, E., (A) 269
STONER, G. L., (O) 16, (A) 136, 372
STORRS, E. E., (A) 502
STOTT, H., (A) 483
SUCHIN, J., (A) 502
SUGIYAMA, K., (A) 275
SUH, J. H., (A) 376
SUN, Y. X., (A) 367
SUN ZHEN-DE, (A) 135
SUNDAR RAO, P. S. S., (A) 133
SURI, S., (A) 471
SUTHERLAND, I., (A) 483
SZABADOS, L., (O) 42

TALONU, M. T., (A) 478
TALUKDER, G., (A) 488
TALWAR, N., (A) 487
TARABINI-CASTELLANI, G., (A) 136, 136, 479, 479, 480
TARABINI-CASTELLANI, G. L., (A) 136, 136, 479, 479, 480
TATSUKAWA, H., (O) 302
TAYLOR, P. M., (O) 31
TAYLOR, V. E., (A) 126
TEIXEIRA, A. C., (A) 283
TEKANI, B. U., (A) 128
TELLO, E. E., (A) 141
TEN DAM, H. G., (A) 145
TERENCIO DE LAS AGUAS, J., (A) 142
THANGARAJ, R. H., (N) 350, 461
THEOPHILUS, S., (A) 126
THOMAS, J., (O) 1, (A) 277
THOMPSON, D. E., (A) 484
THOMPSON, E. J., (A) 284
THOMPSON, P., (B) 266
TIWARI, V. D., (A) 360, 475
TOMAN, K., (O) 205
TOMECKI, K. J., (A) 126
TOMPE, D. B. S., (A) 128
TONELLO, C. J. S., (O) 393
TORRIGIANI, G., (A) 128
TOUW, J., (A) 136
TRIPATHY, N., (A) 128
TRIPATHY, S. P., (A) 487
TROY, J. L., (A) 272
TSAI, L. C., (A) 370
TSENG, C. H., (A) 272
TSUTSUMI, S., (A) 269
TURJANSKI, L., (A) 470
TURK, J. L., (A) 482

UPADHYAY, S., (A) 377

VAIDYA, M. C., (A) 129, 134, 140, 273
VAIDYANATHAN, B., (A) 487
VAN DER MEULEN, J., (C) 457
VANDIVIERE, H. M., (A) 284
VAN LANDINGHAM, R., (A) 139
VAN LOO, G., (A) 125
VAN RENSBURG, A. J., (A) 360
VAN RENSBURG, C. E., (A) 360
VAN ROOD, J. J., (A) 134, 140
VASUDEVAN, D. M., (A) 130
VELIATH, A. J., (A) 137
VENKATESAN, K., (A) 127, 128, (O) 307, (A) 474
VERAS, J. R., (A) 502
VERMA, N., (A) 475
VIJAYAKUMAR, T., (A) 130

VILLA, S. Z., (A) 480
VITHAYASAI, V., (A) 515

WADE, H. H., (E) 64
WADEE, A. A., (O) 159
WAHBA, A., (A) 131, 136
WALKER, L. L., (A) 139
WALLACH, D., (A) 475
WALSH, G. P., (A) 500
WALTER, J., (A) 128
WALTHER, R. R., (A) 272
WANG HEYING, (A) 367
WANGE, H. M., (A) 128
WARNDORFF, J., (O) 16
WARNDORFF, T., (A) 469
WATSON, S. R., (A) 515
WAUDBY, H., (O) 167
WEISMAN, M. H., (A) 127
WELCH, T. M., (A) 138, 139
WENDT, S. L., (A) 284
WHEATE, H., (N) 353, 460, 461
WHEELER, P. R., (A) 374
WIDEBÄCK, K., (A) 138
WILKINSON, F. F., (A) 127, 127
WOLF, R. H., (A) 500
WOOD, P. H. N., (A) 142
WRIGHT, E. P., (C) 455
WRIGHT, P., (A) 468
WU QINXUE, (A) 367

YAAQUB, C. X., (A) 480
YAMAMOTO, Y., (A) 368
YANGCO, B. G., (A) 378
YAO-DE, Z., (A) 368
YAWALKAR, S. J., (O) 393
YE GAN-YUN, (E) 218, (N) 353, 367
YE SHUNZHANG, (A) 367
YOKOYAMA, M., (A) 272
YONEDA, K., (A) 508
YOSHIDA, T., (A) 516
YOSHINA, Y., (A) 503
YOUNG, D. B., (A) 198, (O) 279

ZAHRA, A., (A) 359
ZAI, M. U., (A) 483
ZAMBRANO, T., (A) 368
ZHANG YONGFA, (A) 367
ZHENG, T.-S., (A) 142

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Adenosine triphosphate (ATP),
content in *M. leprae*. DHOPLE, A. M. and HANKS, J. H. ....(O) 57

Africa,
leprosy control in The Gambia. Meesters, H. J. R. ....(A) 140

American Leprosy Missions (ALM),
receives 1981 Damien-Dutton Award ....(N) 347
Workshop on Training ....(N) 265
25th International Seminar on Leprosy ....(N) 265
75th anniversary ....(N) 356

Amyloidosis,
in leprosy. Gupta, J. C. and Pandya, P. K. ....(A) 129
renal, histological and biochemical assessment of severity of. Bhuyan, U. N. ....(A) 486
SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders. Lack of association with amyloid disease. Scheinberg, M. A. and Benson, M. D. ....(A) 474
serum electrophoretic pattern in, complicating tuberculosis. Patra, S. B., *et al.* ....(A) 488

Andrade, Roberto Nuñez,
obituary. Saúl, A. ....(Ob) 83

Antibodies,
against *M. leprae* antigen 7 from birth to 18 months of age: an indicator of intrauterine infection in leprosy. Mathias, C., *et al.* ....(A) 133
demonstration of, reacting with different determinants on *M. leprae* antigen 7. Harboe, M., *et al.* ....(A) 147
enzyme-linked immunosorbent assay (ELISA): a study of . . . to *M. tuberculosis*. Grange, J. M., *et al.* ....(A) 144
mycobacterial, response to nine, for an . . . common to tuberculosis and lepromatous leprosy. Kaplan, M. H. and Chase, M. W. ....(A) 275
monoclonal, antigenic relationships between *M. leprae* and other mycobacteria defined by absorbed leprosy sera and. Gillis, T. P. and Buchanan, T. M. ....(A) 504
responses *in vitro* by BCG, *M. leprae*, and *Corynebacterium parvum*, phagosome/lysosome fusion. Brown, C. A., *et al.* ....(A) 275
use of the ELISA to screen for anti-thymocyte and anti-β_2-microglobulin, in leprosy and SLE. Bahr, G. M., *et al.* ....(A) 273

Antigen(s),
Australian, incidence of, in leprosy. Lenka, M. R., *et al.* ....(A) 271
—, subtypes of, in leprosy in São Paulo. Ottati, S. and Candeias, J. A. N. ....(A) 272
cutaneous responses to, and irritants in patients of leprosy. Kumar, B., *et al.* ....(A) 132
Dharmendra, assessment of. Sinha, S., *et al.* ....(A) 276
—, —, diluted. Kumar, B., *et al.* ....(A) 132
histocompatability, in leprosy. Park, E. S., *et al.* ....(A) 376
HLA, distribution of, in Ticuna Indians of Brazil. Lawrence, D. N., *et al.* ....(A) 132
M. leprae . . . 7. HARBOE, M., *et al.* ....(O) 147
—, comparison of 22 species of mycobacteria by immunodiffusion against an absorbed leprosy serum. GILLIS, T. P., *et al.* ....(O) 287
— specific, obtained by lithium acetate extraction procedure. BUCHANAN, T. M., *et al.* ....(C) 88
—, —. HARBOE, M. and CLOSS, O. ....(O) 85
mycobacterial, *in vitro* stimulation of human lymphocytes with. WRIGHT, E. P. and RANGARAJAN, R. ....(C) 455
reactivity to, of various mycobacterial species. Vandiviere, H. M., *et al.* ....(A) 284

Argentina,
antileprosy battle in Sante Fe. Lehrer, A. B. and Bonnucci, N. E. ....(A) 483
XXV Conference of the International Union against tuberculosis. ....(N) 97

Grupos de Investigación de la Enfermedad de Hansen (GRIHAN).....(N) 97
La Sociedad Argentina de Leprología conference.....(N) 261

Armadillo (nine-banded) (*Dasypus novemcinctus*),
— grown *M. leprae* to study antigenic detail. HARBOE, M. and CLOSS, O. .....(C) 85
ATP content harvested from, using firefly bioluminescence method. DHOPLE, M. and HANKS, J. H.....(O) 57
case of natural splenic mycobacteriosis in, with histopathologic and tinctorial characteristics similar to leprosy. Resoagli, E. H., *et al.* .....(A) 139
feral, mycobacteria obtained from, failure to detect *o*-diphenoloxidase in. Prabhakaran, K., *et al.* .....(A) 281
in captivity: prevention of losses due to parasitic diseases. KAZDA, J. M.....(C) 345
infected, lipid constituents of *M. leprae* isolated from. Asselineau, C., *et al.* .....(A) 372
liver of, occurrence of superoxide dismutase in *M. leprae* grown on. Kusunose, E., *et al.* .....(A) 278
mycobacterial lipids in biopsies of. YOUNG, D. B.....(O) 199
proteins of, that contaminate *M. leprae* during its purification. Quesada-Pascual, F., *et al.* .....(A) 506

Aspiration cytology,
of lymph nodes in leprosy. Gupta, S. K., *et al.* .....(A) 9

Australia,
— wide leprosy seminar. .....(N) 460
Leprosy in Tropical Australia. Hargrave, J. C. and Jones, E. R. .....(B) 115

Bacterial Index (BI),
choice of skin slit smears for study of . . . and MI. Kaur, S., *et al.* .....(A) 129

BCG,
— vaccination with, borderline tuberculoid leprosy following. STONER, G. L., *et al.* ..(O) 16
—, —, trial of, in South India for tuberculosis prevention. .....(A) 145
—, —, and lepromin-A administered contemporaneously seen in a separated positive association. Tarabini-Castellani, G., *et al.* .....(A) 480
effect of, on protective efficacy of two distinct forms of cell-mediated response to. Rook, G. A. W., *et al.* .....(A) 276
efficacy, of protective, how environmental mycobacteria may predetermine. Stanford, J. L., *et al.* .....(A) 277
granulomatous response of leprosy patients to killed . . . and lepromin. Hans, S. H., *et al.* .....(A) 476
inducing immunity to *M. leprae* in mice. Ganguly, N. K., *et al.* .....(A) 280
inoculation of lepromin-A . . . in cases that are negative to three successive lepromin tests. Tarabini-Castellani, C., *et al.* .....(A) 480
Mitsuda test, in healthy vaccinated cases who were not vaccinated with antituberculous BCG. Tarabini-Castellani, C., *et al.* .....(A) 479
—, with lepromin-A, in cases pre-treated for 6 months with a mixture of . . . and lepromin-A. Tarabini-Castellani, G., *et al.* .....(A) 479
— -primed mouse spleens, cultures of. *Corynebacterium parvum* or *M. leprae* added to. Brown, C. A., *et al.* .....(A) 273
treatment of lepromatous leprosy with. Villa, S. Z., *et al.* .....(A) 480
WHO experts recommend continued use of, against tuberculosis. .....(N) 464

Belgium,
Damien Foundation publishes Atlas of Leprosy Distribution. .....(N) 97
— revises Atlas of Leprosy Distribution. .....(N) 460

Biopsy,
fine needle aspiration. GUPTA, S. K., *et al.* .....(O) 9
from leprosy patients, detection of mycobacterial lipids in. YOUNG, D. B. .....(O) 198

Blood,
low serotonin uptake by platelets in leprosy. SZABADOS, L., *et al.* .....(O) 42
test, evaluation of, for potential to indicate leprosy infection prior to appearance of clinical symptoms. REICH, C. V., *et al.* .....(O) 21

Bone(s),
alterations in, in Hansen's disease. Cardama, J. E., *et al.* .....(A) 484

Artropatia Hanseniana. Moleres Ferrandis, R. ....(A) 472
tarsal . . . disintegration in Hansen's disease patients. Gabrielli, M., *et al.* ....(A) 142

Borderline,
— leprosy, histological course of reactions in, and their outcome. RIDLEY, D. S. and RADIA, K. B. ....(O) 383
— tuberculoid leprosy following BCG vaccination. STONER, G. L., *et al.* ....(O) 16

Brazil,
distribution of HLA antigens in Ticuna Indians. Lawrence, D. N., *et al.* ....(A) 132
situation of endemic Hansen's disease in the state of São Paulo. Belda, W. and Lombardi, C. ....(A) 482

Browne, Stanley G.,
Mister Leprosy, biography of. Thompson, P. ....(B) 266
personal. ....(N) 357

Canada,
Secours aux Lepreux (SLC) becomes member of ILEP. ....(N) 349

Caribbean, The,
surveillance of communicable diseases in, 1979. Hansen's disease. Nalli, G. A. and Pearson, D. A. ....(A) 282

Cat leprosy,
observations of, in New Zealand. Thompson, E. J., *et al.* ....(A) 284

Cells,
mononuclear, effector function of, from leprosy patients. Humphres, R. C., *et al.* ....(A) 514
spindle-shaped leproma, arising from perineurium, a link with Wade's histoid leprosy. Gaulier, A. ....(A) 476
studies on T cell subsets and functions in leprosy. Bach, M.-A., *et al.* ....(A) 475
suppressor, decreased, activity in disseminated granulomatous infections. Artz, R. P., *et al.* ....(A) 465
— T, evidence for *in situ* activation of, in lepromatous leprosy. Mehra, V., *et al.* ....(A) 515

Chemotherapy,
antileprotic action of an extract from "anantamul." Gupta, P. N. ....(A) 469
antimycobacterial activity of 2-acetylpyridine thiosemicarbazones in relation to their antileprosy activity. MORRISON, N. E. and COLLINS, F. M. ....(O) 180
clinical trials with Ciba 1906 in lepromatous leprosy. Anand, L. C., *et al.* ....(A) 360
drug interaction, influence of rifampin and clofazimine on the urinary excretion of DDS. Balakrishnan, S. and Seshadri, P. S. ....(A) 268
effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth. David, H. L., *et al.* ....(A) 122
evaluation of multiple drug regimens in leprosy. Ramu, G., *et al.* ....(A) 363
combined, against *M. leprae* in the mouse. Pattyn, S. R. and Van Loo, G. ....(A) 125
multi-drug, a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH, and thiacetazone in lepromatous cases. Kundu, S. K., *et al.* ....(A) 362
—, treatment for reactions in leprosy. Abdul Razack, E. M. ....(A) 269
of leprosy, present status and future prospects of, based on experience with treating tuberculosis. ACOCELLA, G. ....(E) 331
study on drug interactions. Venkatesan, K. ....(A) 127
treatment of lepromatous leprosy with a combination of rifampin and isoprodian. Colin, M. and de Montaigne, E. ....(A) 269

Children,
leprosy in. Lal, S. ....(A) 268
—, psychodynamic side of. Children's Apperception Test (CAT) study. Chauhan, N. S. and Dhar, U. ....(A) 484
—, study in an urban slum. Jayam, S., *et al.* ....(A) 282
Miyako Islands, FLA-ABS and lepromin tests in, immuno-epidemiological studies on subclinical infection with *M. leprae*. Abe, M., *et al.* ....(A) 503

China, People's Republic of,
decline of leprosy in. SKINSNES, O. ....(C) 341

general condition of work on prevention and treatment of leprosy in. MA HAIDE and YE GAN-YUN. ....(E) 218
ILA President, Dr. Michel F. Lechat, visits China. ....(N) 268
Skinsnes, Dr. O. lectures in. ....(N) 106
WHO Technical Visiting Group visit. ....(N) 353

Cholinesterase,
serum, its genetic variants in leprosy patients. Terencio de las Aguas, J., *et al.* ....(A) 142

Circulating immune complexes (CIC),
detected by Clq solid phase assay in leprosy. NUTI, M., *et al.* ....(O) 27
in cervical cancer: simple method for detection and characterization. Seth, P. and Srinivas, R. V. ....(A) 488

Clinical symptoms of leprosy,
new blood test to indicate leprosy infection prior to appearance of. REICH, C. V., *et al.* ....(O) 21

Clofazimine,
and dapsone, a combination therapy in ENL syndrome. Dutta, R. K. ....(A) 122
after 16 years—the best antileprosy drug? Jacobson, R. R. ....(A) 510
analogs, activity of four against *M. leprae*. Levy, L. ....(A) 362
clinical evaluation of, in vitiligo. Shak, K. C. ....(A) 488
gastro-intestinal side effects of. Lal, S., *et al.* ....(A) 362
in lepra reactions. Imkamp, F. M. J. H. ....(A) 470
in treatment of annular lupus erythematosus. Crovato, F. and Levi, L. ....(A) 377
in treatment of lepromatous leprosy in the United Kingdom. 12-year review of 31 cases. BROWNE, S. G., *et al.* ....(O) 167
intraneural ceroid-like pigment following treatment of lepromatous leprosy with. McDougall, A. C. and Jones, R. L. ....(A) 362
radiological abnormalities of the ileum associated with the use of, in the treatment of skin ulceration due to *M. ulcerans*. de Bergeyck, E., *et al.* ....(A) 122

Clq solid phase assay,
to detect circulating immune complexes in leprosy. NUTI, M., *et al.* ....(O) 21

Contacts, of leprosy patients,
a study of. Govila, A. K. and Kushwah, S. S. ....(A) 140
lepromin reaction in child contacts and non-contacts in Chengalpattu District, Tamil Nadu. Ramu, G., *et al.* ....(A) 141
results of an enzyme-linked immunosorbent assay using arabinomannan from *M. smegmatis*. Miller, R. A. and Buchanan, T. M. ....(A) 506

Corynebacteria,
leprosy-derived, primary structure of the wall peptidoglycan of. Janczura, E., *et al.* ..(A) 372

Cyclophosphamide,
effect of, on course of *M. lepraemurium* infection. Alexander, J. ....(A) 279

Cytology,
aspiration, of lymph nodes in leprosy. GUPTA, S. K., *et al.* ....(O) 9

Damien Dutton Award,
awarded to American Leprosy Missions. ....(N) 347
— to Mr. Robert Watelet. ....(N) 260
list of previous recipients. ....(N) 261

Damien, Father
Damien, the Leper Priest. Neimark, A. E. ....(B) 117

Dapsone,
action of. SEYDEL, J. K. ....(C) 90
and rifampin, changes in neutrophil motility. Anderson, R. and Gatner, E. M. S. ....(A) 360
assaying, in mouse diets. Ellard, G. ....(A) 269
assessment of self-administration of, in urine. Balakrishnan, S. and Christian, M. ....(A) 122
clofazimine and, a combination therapy in ENL syndrome. Dutta, R. K. ....(A) 122
effect of, on blood pyruvate and lactate levels in leprosy patients. Bharadwaj, V. P., *et al.* ....(A) 128

—, on nude mice experimentally infected with *M. leprae*. Bharadwaj, V. P., *et al.* ...(A) 508
erythema multiforme bullosum due to. Dutta, R. K. ....(A) 123
fatal reaction to, during treatment of leprosy. Frey, H. M., *et al.* ....(A) 469
fluorimetric screening of, in urine for drug trials. Balakrishnan, S. ....(A) 121
haemolysis in leprosy. Menezes, S., *et al.* ....(A) 270
-induced hypohaptoglobinemia in lepromatous leprosy patients. SRITHARAN, V., *et al.* (O) 307
in treatment of leprosy patients in Papua New Guinea. Ree, G. H. and Taylor, V. E. (A) 126
in vitro and *in vivo* effects of, on neutrophil and lymphocyte functions. Anderson, R., *et al.* ....(A) 360
optic atrophy and motor neuropathy induced by. Homeida, M., *et al.* ....(A) 361
patient compliance with the administration of. HUIKESHOVEN, H. ....(E) 228
profile of urinary. . ./creatinine ratios after oral dosage with. Ellard, G. A. ....(A) 123
reply to Dr. van der Meulen and Dr. Mock's Letter to the Editor. NAAFS, B. ....(C) 459
reversal reaction, management of, 100 mg daily, the cornerstone. VAN DER MEULEN, J. and MOCK, B. ....(C) 457
self-administration of, by leprosy patients in Ethiopia. Ellard, G. A., *et al.* ....(A) 469
still first choice in leprosy. Modderman, E. S. M. ....(A) 271
study of, in leprosy control. Ko, Y. H. ....(A) 362
toxic psychosis after accidental ingestion of. Krishna Murthy, K. and Raja Babu, K. K. ....(A) 124
trials for chemoprophylaxis of leprosy by, fundamental studies on an artificial DDS-rice. Gidoh, M., *et al.* ....(A) 269
with rifampin 1200 mg once monthly and daily Lamprene®, in treatment of refactory patients with lepromatous leprosy. PAUL, S. and ROSE, E. T. ....(C) 342

Dapsone resistance,
in a population of Bamako (Mali). Baquillon, G., *et al.* ....(A) 268
in Cebu, Philippines. GUINTO, R. S., *et al.* ....(O) 427
in lepromatous leprosy, clofazimine in the treatment of. BROWNE, S. G., *et al.* ....(O) 167
problem of, in leprosy. PEARSON, J. M. H. ....(O) 417
—, the THELEP approach. ....(O) 421
in pregnancy, in leprosy. Duncan, M. E., *et al.* ....(A) 471

Denmark,
joint WHO-ILA meeting. Hastings, R. C. ....(N) 460

Disability(ies),
appreciating the consequences of disease: the *International Classification of Impairments, Disabilities, and Handicaps*. Wood, P. H. N. ....(A) 142
of Hansen's disease. Goncalves, A. ....(A) 485
The Economics of Disability: International Perspectives. Rehabilitation International in cooperation with the United Nations. ....(B) 358

Drug metabolism,
in leprosy. Sharma, S. C., *et al.* ....(A) 126

Dutton, Brother Joseph,
Brother Joseph Dutton, 1843–1931, A Saint for Vermont. Halpern, R. ....(B) 358

East Java,
immunological and clinical features of smear-positive pulmonary tuberculosis in. Kardjito, T. and Grange, J. M. ....(A) 283

Edema,
of extremities. MCDOUGALL, A. C. ....(C) 91
of hands and feet. CRAWFORD, C. L. ....(C) 90

Electron microscopic study,
and biochemical studies of the peribacillary substance of *M. leprae*. Fukunikshi, Y., *et al.* ....(A) 499
on *M. leprae* in nerve lesions in lepromatous leprosy. Choe, J. and Kim, W. I. ....(A) 369

Enna, Carl D.,
retirement of. ....(N) 265

ELISA test(s),
a study of antibodies to *M. tuberculosis* in the IgG, IgA, and IgM classes in tuberculosis, sarcoidosis, and Crohn's disease. Grange, J. M., *et al.* ....(A) 144

an inexpensive, portable battery-operated photometer for the reading of, in microtitration plates. Rook, G. A. and Cameron, C. H. ....(A) 478
use of, to screen for anti-thymocyte and anti-β_2-microglobulin, in leprosy and SLE. Bahr, G. M., *et al.* ....(A) 273

EMR Newsletter,
WHO Eastern Mediterranean Region, new publication begins. ....(N) 264

Epidemiology,
immunogenetics of susceptibility to leprosy, tuberculosis and leishmaniasis, an epidemiological approach. FINE, P. E. M. ....(E) 437
of coronary artery disease among Hansen's disease patients. Moulopoulos, S. D., *et al.* ....(A) 130
study of leprosy through school survey in Surat District (South Gujarat). Bhavsar, B. S. and Mehta, N. R. ....(A) 140

Enzyme(s),
activity in cultured macrophages infected with some species of mycobacteria. Katoh, M. and Matsuo, Y. ....(A) 507
-linked immunosorbent assay using arabinomannan from *M. smegmatis*: results in patients with tuberculosis and leprosy and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. ....(A) 506
occurrence of γ-glutamyl transpeptidase (γ-GT) in mycobacteria. SHETTY, K. T., *et al.* ....(O) 49
occurrence of superoxide dismutase in *M. leprae* grown on armadillo liver. Kusonose, E., *et al.* ....(A) 278
superoxide dismutase in cell-free extracts from *M. leprae* grown on armadillo liver. Kusonose, E., *et al.* ....(A) 373

Erythema nodosum leprosum (ENL),
clofazimine and dapsone, a combination therapy in. Dutta, R. D. ....(A) 122
histology of, variant forms in New Guineans and other ethnic groups. Ridley, D. S., *et al.* ....(A) 371
jaundice occurring as a complication of. Kumar, B., *et al.* ....(A) 129
renal involvement as related to. Bajaa, A. K., *et al.* ....(O) 37
ultrastructure of nerve in. Anthony, J., *et al.* ....(A) 273

Ethiopia,
agreement between Ministry of Health and All Africa Leprosy and Rehabilitation Training Centre (ALERT) for training in leprosy. ....(N) 97
ALERT designated as a WHO Collaborating Centre for Training. ....(N) 349
association of pregnancy and leprosy: new cases, relapse of cured patients, and deterioration in patients on treatment during pregnancy and lactation, a prospective study of 154 pregnancies in 147 Ethiopian women. Duncan, M. E., *et al.* ....(A) 471
self-administration of dapsone by leprosy patients in. Ellard, G. A., *et al.* ....(A) 469

Europe,
recent research activities in mycobacteriology in. Grange, J. M. ....(A) 278

Eye(s),
an assessment of the usefulness and acceptability of eye shields under field conditions. Verma, N. ....(A) 475
blindness due to leprosy. Radnakrishnan, N. and Albert, S. ....(A) 473
cataract surgery in management of late complications of lepromatous leprosy in South Korea. ffytche, T. J. ....(A) 365
complications of, in leprosy, in Prakasam District (Andhra Pradesh). Reddy, S. C., *et al.* ....(A) 367
dapsone-induced optic atrophy and motor neuropathy. Homeida, M., *et al.* ....(A) 361
influence of untreated chronic plastic iridocyclitis on intraocular pressure in leprous patients. Brandt, F., *et al.* ....(A) 364
ocular findings in leprosy patients in an institution in Nepal. Malla, O. K., *et al.* ....(A) 366
ocular involvement in leprosy. Acharya, B. P. ....(A) 271
prevalence of ocular manifestations of leprosy in Port Moresby, Papua New Guinea. Dethlefs, R. ....(A) 365
role of iris changes as a cause of blindness in lepromatous leprosy. ffytche, T. J., *et al.* ....(A) 365

Experimental leprosy,
prothionamide and prothionamide-S-oxide in. MATSUO, Y., *et al.* .....(O) 302
Face,
lepromatous leprosy, clinically localized to one-half of the face. MASCARO, J. M., *et al.* .....(O) 315
reconstructive surgery of deformities in, in leprosy. Teixeira, A. C. .....(A) 283
Feet,
radiological studies on changes of, in calcaneus trabecula in leprosy. Yamamoto, Y. ..(A) 368
surgery of foot drop in leprosy by tibialis posterior transfer. Malaviya, G. N. .....(A) 485
Fernandez reaction,
histology, an appraisal of. THOMAS, J., *et al.* .....(O) 1
reaction in unaffected non-contact children and adolescents tested with human antigen and different concentrations of armadillo antigen in 3 double blind trials. Bechelli, L. M., *et al.* .....(A) 364
Fibers,
unmyelinated, degeneration and regeneration of, in experimental leprous neuropathy. SHETTY, V. P. and ANTIA, N. H. .....(O) 324
Fingers,
in non-lepromatous leprosy. CRAWFORD, C. L. .....(C) 90
Fluorescent staining procedure,
for determining the viability of mycobacterial cells. Kvach, J. T. and Veras, J. R. ....(A) 502
Foot pad(s),
effects of infection with *M. marinum* and *M. leprae* on natural killer cell activity as a manifestation of cell mediated immunity to local infection. Krahenbuhl, J. L. and Humphres, R. C. .....(A) 512
of Swiss mice, inoculated with *M. leprae,* description of morphological changes in unmyelinated fibers. SHETTY, V. P. and ANTIA, N. H. .....(O) 324
France,
Sixth Scientific Meeting of the Association des Epidémiologistes de Langue Française (ADELF). .....(N) 99
γ-glutamyl transpeptidase
activity in *M. leprae* and other mycobacteria. SHETTY, K. T., *et al.* .....(O) 49
Germany, Federal Republic of,
German Leprosy Relief Association (DAHW) appoints Wilhelm Dewald as General Manager. .....(N) 349
World Leprosy Day. .....(N) 99
Guadeloupe (F.W.I.),
detection of leprosy in a district of. Millan, J. .....(A) 141
Hand(s),
deformity of thumb in ulnar paralysis. Palande, D. D. and Gilbie, S. G. .....(A) 377
relative tension and potential excursion of muscles in. Brand, P. W., *et al.* .....(A) 484
surgical treatment for leprotic intrinsic hand muscle paresis. Zheng, T. S. .....(A) 142
Hemolysis,
in leprosy patients. SRITHARAN, V., *et al.* .....(O) 307
Hepatitis,
—-B antigen and antibody in Papua New Guinea. Ree, G. H. and Talanou, M. T. .....(A) 478
Histiocytoma,
leprous. Misra, R. C. .....(A) 133
Histoid leprosy,
clinical and experimental observations. Li Wenzhong, *et al.* .....(A) 367
Wade's spindle shaped leproma cells arising from perineurium, a link with. Gaulier, A. .....(A) 476
Histology,
correlations between clinical elements and, in leprosy. Husser, J. A., *et al.* .....(A) 366
course of reactions in borderline leprosy and their outcome. RIDLEY, D. S. and RADIA, K. B. .....(O) 383

histopathological findings of serial preparation including the total length of nerve extremitas thoracica in leprosy. Koya, G., *et al.* ....(A) 477
histopathological re-examination of 50 discharged patients. Yao-De, Z. ....(A) 368
of ENL, variant forms in New Guinea and other ethnic groups. Ridley, D. S., *et al.* ..(A) 371
of Fernandez reaction. THOMAS, J., *et al.* ....(O) 1

History,
how old is leprosy? Browne, S. G. ....(A) 468

Hormones,
changes in, in human leprosy. Ree, G. H., *et al.* ....(A) 473
profile in lepromatous leprosy. ROLSTON, R., *et al.* ....(O) 31

Hypersensitivity,
dapsone. Tomecki, K. J., *et al.* ....(A) 126
delayed type, development of, in C57B1 and BALB/c mice, effect of cyclophosphamide treatment on. Alexander, J. ....(A) 279
—, failure to induce in long-term treated lepromatous leprosy patients. Smelt, A. H., *et al.* ....(A) 478
—, to mycobacterial antigens. Lovik, M. and Closs, O. ....(A) 477
—, to *M. leprae*, induction of in healthy individuals. Smelt, A. H., *et al.* ....(A) 479

ILEP (International Federation of Anti-Leprosy Associations),
appeal on World Leprosy Day. ....(N) 99
collaboration with ILA for XII International Leprosy Congress, 1983. ....(N) 461

Immune complex(es),
circulating, and tissue, in leprosy. SEHGAL, S. and KUMAR, B. ....(O) 294
—, detected by Clq solid phase assay in leprosy. NUTI, M., *et al.* ....(O) 27

Immune response,
humoral, studies on, in leprosy. Yokoyama, M., *et al.* ....(A) 272
—, in mice, assessment of, immune response to *M. lepraemurium*. Navalkar, R. G. and Kanchana, M. V. ....(A) 280
—, further studies on the assessment of immune response to *M. leprae*. ....(A) 280

Immunity,
BCG induced, to *M. leprae*, in mice. Ganguly, N. K., *et al.* ....(A) 280
protective, delayed type hypersensitivity to mycobacterial antigens without, a failure to produce the right specificity or the right type of immune reaction. Lovik, M. and Closs, O. ....(A) 477
—, preliminary immunological studies in search of correlates of, carried out on Iranian leprosy patients and their families. Stanford, J. L., *et al.* ....(A) 277

Immunity, cell mediated (CMI),
a study of, in leprosy. Dubey, G. K. ....(A) 369
immunological status of maculoanesthetic leprosy: leucocyte migration inhibition test as a measure of. Rao, S. S. L. and Rao, P. R. ....(A) 473
in cutaneous tuberculosis. Sengupta, L. K., *et al.* ....(A) 488
quantitative DNCB epicutaneous sensitization in leprosy patients and controls. Sivamani, S., *et al.* ....(A) 272
to local infection, manifestation of; effects of foot pad infection with *M. marinum* and *M. leprae* on natural killer cell activity. Krahenbuhl, J. L. and Humphres, R. C. ..(A) 512

Immunogenetics,
of susceptibility to leprosy, tuberculosis, and leishmaniasis, an epidemiological perspective. FINE, P. E. M. ....(E) 437

Immunology,
immunological aspects of leprosy. Harboe, M. and Closs, O. ....(A) 477
recognition, immunological, and effector mechanisms in infectious diseases. WHO. ...(A) 275
study on leprosy, T and B lymphocytes of peripheral blood. Bao-Hong Ji. ....(A) 274

Indeterminate leprosy,
an experience on treatment of five intractable cases of. Sohn, J. S., *et al.* ....(A) 365
should . . . ever be diagnosed? PETTIT, J. H. S. ....(C) 95

India,
Acworth Leprosy Hospital, Tenth Workshop on Leprosy. ....(N) 351

—, Society for Research, Rehabilitation, and Education in Leprosy issues ten year report. ....(N) 261
All India Leprosy Workers' Conference. ....(N) 350
an analysis into the trends of reconstructive surgery in Gudiyatham Taluk, a leprosy control area. Jesudasan, S., *et al.* ....(A) 376
Asian Seminar on Vocational Rehabilitation of Leprosy Patients. ....(N) 352
Association of Microbiologists of India and Foundation for Medical Research sponsors international symposium on *M. leprae*. ....(N) 262
Bombay Leprosy Project 1979 annual report. ....(N) 100
Central JALMA Institute for Leprosy 1979 annual report. ....(N) 101
Consensus Conference on Classification of Leprosy. ....(N) 103
deformities in leprosy patients of Indian Armed Forces treated/reviewed at Military Hospital, Agra. Tiwari, V. D. and Mehta, R. P. ....(A) 475
Gandhi Memorial Leprosy Foundation summary of 1979 activities. ....(N) 101
Hemerijckx Government Leprosy Centre Silver Jubilee. ....(N) 103
Hind Kusht Nivaran Sangh, Andhra Pradesh Branch, and A.M.G. India International, second seminar on leprosy. ....(N) 349
—, activities of. ....(N) 102
—, annual general meeting. ....(N) 351
—, annual report. ....(N) 101
honors to three outstanding leprologists. ....(N) 462
incidence of glucose-6-phosphate dehydrogenase deficiency in a hospital population of Delhi. Madan, N., *et al.* ....(A) 487
Indian Association of Leprologists. ....(N) 102
XII International Leprosy Congress, call for abstracts. ....(N) 461
—, to be held 21–26 November 1983 in New Delhi. ....(N) 352
leprosy in, an analysis of 4 years of O.P.D. data. Mani, M. Z. and Mathew, M. ....(A) 483
— Jaipur. A clinical and epidemiological study. Mathur, N. K., *et al.* ....(A) 483
The Leprosy Mission. ....(N) 350
—, in Southern Asia. ....(N) 103
National Leprosy Organisation publication. ....(B) 116
prevalence of leprosy, among inpatients in general hospitals, a survey in Bombay. Ganapati, R., *et al.* ....(A) 281
—, among slum dwellers. Marshall, J. T., *et al.* ....(A) 281
Prime Minister Indira Gandhi calls for war on leprosy. ....(N) 352
Schieffelin Leprosy Research and Training Centre, 1982 course schedule. ....(N) 461
—, Karigiri Neuritis Workshop. ....(N) 99
—, Silver Jubilee. ....(N) 351
survey of eye complications in leprosy in Prakasam District (Andhra Pradesh). Reddy, S. C., *et al.* ....(A) 367
Tamil Nadu State Branch State Council Meeting. ....(N) 351
IX Workshop on Leprosy and 10th anniversary, Acworth Leprosy Hospital Society for Research, Rehabilitation and Education. ....(N) 103

Indonesia,
leprosy in. Harahap, M. ....(A) 483

INTERNATIONAL JOURNAL OF LEPROSY,
acknowledgment. ....(—) 146
....(—) 285
....(—) 382
....(—) 533
reviewers, list of. ....(—) 467
statement of financial condition. ....(—) 379
statement of ownership, management and circulation. ....(—) 519

International Leprosy Association,
at 50 years. LECHAT, M. F. ....(E) 60
formation of. COCHRANE, R. G. ....(E) 67
organization and membership. ....(—) 519
presidents of. ....(—) 72

International Leprosy Congress, XII,
first intimation. ....(N) 460
call for abstracts. ....(N) 461
ILEP collaboration. ....(N) 461

Iran,
preliminary immunological studies in search of correlates of protective immunity carried out on families in. Stanford, J. L., *et al.* ....(A) 277

Ireland,
UNESCO Science Prize for 1980 awarded to group from Laboratories of the Medical Research Council of Ireland. ....(N) 262

Italy,
European Leprosy Symposium. ....(N) 262
ILEP, 35th meeting of the Medical Commission in Rome. ....(N) 462
Pope John Paul II meets with ILEP members. ....(N) 104
symposium on leprosy in light-skinned people. ....(N) 462

Japan,
Japanese leprosy conference, Tokyo. ....(N) 104
Miyako Islands, FLA-ABS and lepromin tests in school children. Immuno-epidemiological studies on subclinical infection with *M. leprae*. ....(A) 503
U.S.-Japan Cooperative Medical Science Program, Sixteenth Joint Leprosy Conference, Bethesda, Maryland, 13–14 July 1981. ....(—) 490

Jaundice,
occurring as a complication of ENL (a report of cases). Kumar, B., *et al.* ....(A) 129

Kenya,
pulmonary tuberculosis in, a third study of case-finding methods. Nsanzumuhire, H., *et al.* ....(A) 483

Kirchheimer, Dr. W. F.,
personal. ....(N) 464

Korea,
cataract surgery in the management of late complications of lepromatous leprosy in South Korea. ffytche, T. J. ....(A) 365

Larynx,
a clinico-pathological study of laryngeal lesions in 30 cases of leprosy. Gupta, J. C., *et al.* ....(A) 129

Leiker, Dr. Derek Luitjen,
personal. ....(N) 264

Leishmaniasis,
immunogenetics of susceptibility to leprosy, tuberculosis, and . . . an epidemiological perspective. FINE, P. E. M. ....(E) 437

Leonard Wood Memorial,
conference on leprosy in Manila, Philippine Islands, 9–23 January 1931. WADE, H. H. and GESHUE-TAYLOR, G. ....(E) 64
new leadership. ....(N) 465

Lepromatous leprosy,
as a model of Schwann cell pathology and lysosomal activity. Dastur, D. K. and Porwal, G. L. ....(A) 369
clinically localized to one-half of the face. MASCARO, J. M., *et al.* ....(O) 315
clofazimine (Lamprene, B663) in the treatment of. BROWNE, S. G., *et al.* ....(O) 167
controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-daily rifampin. OPROMOLLA, D. V. A. ....(O) 393
dapsone-induced hypohaptoglobinemia in. SRITHARAN, V., *et al.* ....(O) 307
evidence for *in situ* activation of suppressor T cells. Mehra, V., *et al.* ....(A) 515
failure to induce delayed-type hypersensitivity to *M. leprae* in long-term treated patients. Smelt, A. H. M., *et al.* ....(A) 478
gonadal function in. Shilo, S., *et al.* ....(A) 474

effect of single dose (1500 mg) rifampin on infectivity of patients with. Girdhar, B. K., *et al.* ....(A) 123
hormone profile in. ROLSTON, R., *et al.* ....(O) 31
impairment of immunoregulatory control over B lymphocyte. Bullock, W. E., *et al.* ..(A) 515
intra-neural ceroid-like pigment following treatment with clofazimine (B663; Lamprene). McDougall, A. C. and Jones, R. L. ....(A) 362
in vivo and *in vitro* effects of levamisole on patients with. SHER, R. ....(O) 159
light and electron microscopic study on *M. leprae* in nerves. Choe, J. and Kim, W. I. (A) 369
multiple drug therapy—a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH, and thiacetazone in. Kundu, S. K., *et al.* ..(A) 362
neutrophil chemotactic responses in. Wahba, A., *et al.* ....(A) 136
polar, adherent suppressor cells in. Ridel, P. R., *et al.* ....(C) 91
presenting as orchitis. Akhtar, M., *et al.* ....(A) 127
renal functional status in. BAJAJ, A. K., *et al.* ....(O) 37
—. Sritharan, V., *et al.* ....(A) 474
serological and immunohistological studies on. Kano, K., *et al.* ....(A) 370
study of percutaneous renal biopsy in. Gupta, S. C., *et al.* ....(A) 369
subpolar. . . . a histologic and ultrastructural study of a patient. Sanabria Negrin, J. G., *et al.* ....(A) 135
treatment of, with combination of rifampin and isoprodian. Colin, M. and de Montaigne, E. ....(A) 269
—. with BCG, Villa, S. Z., *et al.* ....(A) 480
Wade's histoid. Rampure, A. M. and Bhargava, M. K. ....(A) 134
with rifampin 1200 mg once monthly, daily Lamprene®, and dapsone in treatment of refractory patients with. PAUL, S. and ROSE, E. T. ....(C) 342

Lepromin,
antigenic analysis of, assessment of Dharmendra antigen. Sinha, S., *et al.* ....(A) 276
-A-BCG, inoculation of, in cases that are negative to three successive tests. Tarabini-Castellani, G., *et al.* ....(A) 480
BCG vaccination and . . . -A administered contemporaneously seen in a separately positive association. Tarabini-Castellani, G., *et al.* ....(A) 480
double blind trials to study the . . . scar in leprosy patients and in children and adolescent non-contacts, tested with human antigen and different concentrations of armadillo antigen. Bechelli, L. M., *et al.* ....(A) 363
early Fernandez reaction in unaffected noncontact children and adolescents tested with human antigen and different concentrations of armadillo antigen in double blind trials. Bechelli, L. M., *et al.* ....(A) 364
granulomatous response of leprosy patients to . . . and killed BCG. Han, S. H. ....(A) 476
influence of sulfone therapy on . . . reaction. Ramu, G., *et al.* ....(A) 126
Mitsuda reaction, comparative study with integral human and armadillo . . . , in 50 patients with leprosy. Zambrano, T., *et al.* ....(A) 368
Mitsuda test, with lepromin A, in healthy vaccinated cases who were not vaccinated with the anti-tuberculosis BCG. Tarabini-Castellani, G., *et al.* ....(A) 479
—, in cases pre-treated for 6 months with a mixture of lepromin-A and BCG. Tarabini-Castellani, G., *et al.* ....(A) 479
reaction, early. THOMAS, J., *et al.* ....(O) 1
-reaction in child contacts of leprosy patients and non-contact children in Chengalpattu District, Tamil Nadu. Ramu, G., *et al.* ....(A) 141
recommended safety requirements for the preparation of, WHO memorandum. Bloom, B. R., *et al.* ....(A) 128
results of the . . . test using human (H) and armadillo lepromins. Tarabini-Castellani, G., *et al.* ....(A) 136

Leprosy,
A Guide to Leprosy Control. World Health Organization. ....(B) 113
age of onset. Guha, P. K., *et al.* ....(A) 281
an unusual factor-X inhibitor in. ....(A) 366
—and syphilis, a case report. Nsibambi, J. K. ....(A) 473
atlas of information on, published by the Damien Foundation. ....(N) 97
bacterial persistence in. TOMAN, K. ....(O) 205

blindness due to. Radnakrishnan, N. and Albert, S. ....(A) 473
changing attitudes to. Middle East Health Supply and Service. ....(A) 120
chemotaxis in. Martínez-Palacios, B. N. ....(A) 276
circulating immune complexes in. NUTI, M., *et al.* ....(O) 27
Clq solid phase assay in. NUTI, M., *et al.* ....(O) 27
complement profile in. Kumar, B., *et al.* ....(A) 132
control of, a study of DDS test in urine. Yo, Y. H. ....(A) 362
—, chimeras and possibilities. Browne, S. G. ....(A) 120
—, role of school survey in. Chandra, S., *et al.* ....(A) 482
decline of, in China. SKINSNES, O. K. ....(C) 341
deformities in patients of Indian Armed Forces treated/reviewed at Military Hospital, Agra. Towari, V. D. and Mehta, R. P. ....(A) 475
detection of, prior to appearance of clinical symptoms with new blood test. REICH, C. V., *et al.* ....(O) 21
diabetic status in. Nigam, P., *et al.* ....(A) 473
—, down but not out. Garfield, E. ....(A) 120
genetic diathesis for. Guha, P. K., *et al.* ....(A) 482
histocompatability antigens of. Park, E. S., *et al.* ....(A) 376
hormonal changes in. Ree, G. H., *et al.* ....(A) 473
how old is . . . ? Browne, S. G. ....(A) 468
hypothesis: do phases of immunosuppression during a *M. leprae* infection determine the spectrum of? Stoner, G. L. ....(A) 372
immunogenetics of susceptibility to . . . , tuberculosis, and leishmaniasis. an epidemiological perspective. FINE, P. E. M. ....(E) 437
immunology of. Navalkar, R. G. ....(A) 134
in an albino. Pannikar, V. K. and Arunthathi, S. ....(A) 272
in Indonesia. Harahap, M. ....(A) 483
in Murcia Province, Spain. Castro Diez, M. C., *et al.* ....(A) 281
knowledge about, among leprosy patients. Raj, V., *et al.* ....(A) 377
Leprosy in the Dark Skin. Leiker, D. L. ....(B) 116
Leprosy in Tropical Australia. Hargrave, J. C. and Jones, E. R. ....(B) 115
Leprosy-Tuberculosis Eradication. Freerksen, E. and Rosenfeld, M. ....(B) 114
looking out for. Browne, S. G. ....(A) 364
low serotonin uptake by platelets, prevention of. SZABADOS, L., *et al.* ....(O) 42
mononuclear cell series in, an ultrastructural report. Ridley, M. J. ....(A) 371
natural suppressor cells in. Nath, I. ....(A) 134
numerical changes in T cell subsets in. Izumi, S., *et al.* ....(A) 275
patients with and family contacts of, results of an enzyme-linked immunosorbent assay using arabinomannan from *M. smegmatis*. Miller, R. A. and Buchanan, T. M. ....(A) 506
psychological reactions to. Behere, P. B. ....(A) 376
psychosomatics of. Ree, G. H. ....(A) 121
radiological studies on changes in calcaneus trabecula in. Yamamoto, Y. ....(A) 368
respiratory reflexes in. MALIK, S. K., *et al.* ....(C) 94
rheumatic manifestations of. Albert, D. A., *et al.* ....(A) 127
rising incidence of, in the U.S.A. Levis, W. R. and Hedrick, J. L. ....(A) 376
serum atypical pseudocholinesterase and. Navarette, J. I., *et al.* ....(A) 141
serum lysozyme in. Naik, S. S. and Gurnani, S. ....(A) 130
serum migration inhibitory activity in patients. Rea, T. H. and Yoshida, T. ....(A) 516
serum protein in. Parvez, M., *et al.* ....(A) 130
studies on T cell subsets and functions in. Bach, M.-A., *et al.* ....(A) 475
study of estimation of serum alpha-1-antitrypsin in various forms of. Singhal, A. L., *et al.* ....(A) 474
survey on incidence of in Geoje Island. Park, K. W. ....(A) 376
trends of reconstructive surgery in Gudiyatham Taluk, a control center. Jesudasan, S., *et al.* ....(A) 376
update on. Hargrave, J. C. ....(A) 359

Lesions,
evolution of nasal mucosal . . . in leprosy. Mehta, L., *et al.* ....(A) 271
isolated plantar and palmar . . . of tuberculoid leprosy. Laja, A. O. and Soyinka, F. ..(A) 271

Leukocyte,
migration inhibition test of, in leprosy patients across the spectrum of leprosy. Sivamani, S., *et al.* .....(A) 135

Levamisole,
in vivo and *in vitro* effect of, on patients with lepromatous leprosy. SHER, R., *et al.* ..(O) 159
rifampicina asociada a. Wilkinson, F. and Liturri, M. .....(A) 127
therapeutic trial of, in leprosy patients. Kim, W. S. and Cinn, Y. W. .....(A) 361

Lewis rat(s),
neonatally thymectomized, relationship between T cell population in, and susceptibility to infection with *M. leprae*. FIELDSTEEL, A. H., *et al.* .....(O) 317

Liberia,
Conference on Integration of Leprosy and Tuberculosis Services. .....(N) 104

Libya,
leprosy in. Malhotra, Y. K. and Kanwar, A. J. .....(A) 140

Lipids,
—, and lipoprotein profiles in leprosy. DEVI, C. S., *et al.* .....(C) 344
constituents of *M. leprae* isolated from experimentally infected armadillos. Asselineau, C., *et al.* .....(A) 372
detection of mycobacterial . . . in skin biopsies from leprosy patients. YOUNG, D. B. (O) 198

Lithium acetate extraction,
procedure to obtain extract containing *M. leprae* specific antigen. HARBOE, M. and CLOSS, O. .....(C) 84
reply to Dr. Harboe's and Dr. Closs's Letter to the editor. BUCHANAN, T. M., *et al.* .....(C) 88

Liver,
damage, a study of, in leprosy patients during lepra reaction. Kim, D. K. .....(A) 366
in leprosy, functional changes. Robins, K., *et al.* .....(A) 130
lesions in reaction states in leprosy. Gharpuray, S. M., *et al.* .....(A) 472

Lymph node(s),
aspiration cytology of, in leprosy. GUPTA, S. K., *et al.* .....(O) 9
disorders, in lepromatous patients. Piva, J. R. and de Perez Nardini, S. .....(A) 134

Lymphocytes,
B, impairment of immunoregulatory control over function of, in lepromatous leprosy. Bullock, W. E., *et al.* .....(A) 515
human, *in vitro* stimulation of, with mycobacterial antigens. WRIGHT, E. P. and RANGARAJAN, R. .....(C) 455
selective loss of *M. leprae* responsiveness of circulating . . . in primary neuritic leprosy. Nath, I., *et al.* .....(A) 370
status of circulating "T" lymphocyte population in leprosy. .....(A) 135
study on T and B, of peripheral blood, immunological study of leprosy. Bao-Hong Ji. (A) 274
suppressive effect of *M. leprae* on the *in vitro* proliferative responses of, from patients with leprosy. Nath, I. and Singh, R. .....(A) 133

Lysosome(s),
lepromatous leprosy as a model of Schwann cell pathology and lysosomal activity. Dastur, D. K. and Porwal, G. L. .....(A) 369

Macrophage(s),
—, culture from untreated leprosy cases. Veliath, A. J., *et al.* .....(A) 137
—, cultured, infected with some species of mycobacteria, lysosomal enzyme activity in. Katoh, M. and Matsuo, V. .....(A) 507
uptake of ^{3}H-thymidine in *M. leprae* inoculated mouse . . . cultures as a rapid indicator of bacillary viability. SATHISH, M. and NATH, I. .....(O) 187

Malaria,
cloning of naturally occurring mixed infections of parasites of. Rosario, V. .....(A) 378

Malaysia,
Malaysian Leprosy Relief Association. .....(N) 104

Mangabey monkey (*Cercocebus torquatus atys*),
leprosy in. Meyers, W. M., *et al.* .....(A) 500

Mexico,
leprosy workshop held in Mexicali. ....(N) 352
XVI meeting of Mexican Leprosy Society. ....(N) 352
two national associations on leprosy. ....(N) 104

Mice,
ATP content harvested from (nude), using firefly bioluminescence method. DHOPLE, M. and HANKS, J. H. ....(O) 57
assaying dapsone in diets of. Ellard, G. A. ....(A) 269
C57B1 and BALB/c, effect of cyclophosphamide treatment on course of *M. lepraemurium* infection. Alexander, J. ....(A) 279
intact mouse as a host for the detection of small numbers of viable *M. leprae* in the presence of large numbers of heat-killed *M. leprae*. Fieldsteel, A. H. ....(A) 490
lack of correlation between antigen-specific cellular reactions and resistance to M. *lepraemurium* infection in. Curtis, J., *et al.* ....(A) 482
normal, thymectomized, irradiated and thymus transplanted *M. leprae* infection in. Kaur, S., *et al.* ....(A) 482
nude, study of chemotherapy of leprosy with. Kohsaka, K., *et al.* ....(A) 508
survival of BALB/c mice after intraperitoneal infection with *M. lepraemurium*. Levy, L., *et al.* ....(A) 138
viability of *M. leprae* after multiplication in. ....(A) 139

Mitsuda reaction,
histology and significance of. Thomas, J., *et al.* ....(A) 277

Morocco,
fifth meeting of Association des Leprologues de Langue Française. ....(N) 463

Morphological Index (MI),
choice of slit smears for study of BI and MI. Kaur, S., *et al.* ....(A) 129

Muscle(s),
striated, pathologic changes in, in leprosy. Kaur, S., *et al.* ....(A) 275
relative tension and potential excursion of, in forearm and hand. Brand, P., *et al.* ....(A) 484

Mycobacteria,
antigenic relationships between *M. leprae* and other . . . defined by absorbed leprosy sera and monoclonal antibodies. Gillis, T. P. and Buchanan, T. M. ....(A) 504
comparison of 22 species of, by immunodiffusion against an absorbed reference leprosy serum. Gillis, T. P., *et al.* ....(A) 287
environmental, predetermination of efficacy of BCG. Stanford, J. L., *et al.* ....(A) 277
failure to detect *o*-diphenoloxidase in cultivable mycobacteria obtained from feral armadillos. Prabhakaran, K., *et al.* ....(A) 281
fluorescent staining procedure for determining viability of cells of. Kvach, J. T. and Veras, J. R. ....(A) 502
killed, immunogenicity of. Rook, G. A. W. ....(A) 276
lysosomal enzyme activity in cultured macrophages infected with some species of. Katoh, M. and Matsuo, Y. ....(A) 507
multivariate analysis of the activity of rifamycins against rapidly growing . . . to define an *in vitro* screening model for their activity against *M. leprae*. Pattyn, S. R. and Hebrant, F. ....(A) 373
Mycobacterial Diseases, Grange, J. M. ....(B) 114
nontuberculous, epidemiology of infection by, isolation of potentially pathogenic mycobacteria from aerosols. Wendt, S. L., *et al.* ....(A) 284
profiles of skin test reactivity to antigens of various species of, in human population and in experimental infections. Vandiviere, H. M., *et al.* ....(A) 284

Mycobacterium avium-intracellulare,
rapid radiometric method for determining drug susceptibility of. Yangco, G. G., *et al.* (A) 378

Mycobacterium chelonei,
resistant cutaneous infection caused by. Fenske, N. A. and Millns, J. L. ....(A) 283

Mycobacterium leprae,
adenosine triphosphate content in. DHOPLE, A. M. and HANKS, J. H. ....(O) 57
a novel glycolipid from, possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. ....(A) 504

antigenic relationships with other mycobacteria defined by absorbed leprosy sera and monoclonal antibodies. Gillis, T. P. and Buchanan, T. M. ....(A) 504
ATP content and other characteristics of. Dhople, A. M., *et al.* ....(A) 502
contamination of, by armadillo proteins, during its purification, quantitation and characterization. Quesada-Pascual, F., *et al.* ....(A) 506
cultivable precursors of *M. leprae*. Chatterjee, B. R. ....(A) 137
discharge of, in milk of leprosy patients. Girdhar, A., *et al.* ....(A) 472
effect of, on lymphocyte proliferation. Touw, J., *et al.* ....(A) 136
electron-microscopic and biochemical studies of peribacillary substance of. Fukunishi, Y., *et al.* ....(A) 499
evaluation of fluorescent microscopy for detection of. Hardas, U. and Lele, V. ....(A) 370
γ-glutamyl transpeptidase activity in. SHETTY, K. T., *et al.* ....(O) 49
immuno-epidemiological studies with. FDA-ABS and lepromin tests in school children in the Miyako Islands. Abe, M., *et al.* ....(A) 503
immunogenicity of, effect of purification steps. Shepard, C. C., *et al.* ....(A) 371
inhibition of the incorporation of ^{3}H DOPA, by desoxyfructo-serotonin. Jayaraman, P., *et al.* ....(A) 124
intact mouse as a host for the detection of small numbers of viable . . . in the presence of large numbers of heat killed. Fieldsteel, A. H., *et al.* ....(A) 499
isolation and identification of mycolic acids in . . . and *M. lepraemurium*. KUSAKA, T., *et al.* ....(O) 406
paracrystalline inclusions in. David, H. L., *et al.* ....(A) 372
parameters influencing the *in vitro* growth of. PORTAELS, F. and PATTYN, S. R. ....(O) 194
persister, after introductory rifampin followed by dapsone therapy. Sreevasta, B. K., *et al.* ....(A) 470
relationship between T-cell population in neonatally thymectomized Lewis rats and susceptibility to infection with. FIELDSTEEL, A. H., *et al.* ....(O) 317
-specific antigen. HARBOE, M. and CLOSS, O. ....(C) 84
suppressive effect of, on the in vitro proliferative responses of lymphocytes from patients with leprosy. Nath, I. and Singh, R. ....(A) 133
viability of, after multiplication in mice. Welch, T. M., *et al.* ....(A) 139

***Mycobacterium lepraemurium*,**
effect of vitamins on cultivation of, in axenic liquid medium and its implication in the culture of *M. leprae*. ....(A) 502
growth of, in cell-free liquid medium containing soluble starch: evaluation by generation time and morphological observation. Sengupta, U. and Nakamura, M. ....(A) 279
host-grown, energy coupling mechanisms in. Ishaque, M., *et al.* ....(A) 481
identification of, use of wall-bound mycolic acids. Young, D. B. ....(A) 279
isolation and identification of mycolic acids in *M. leprae* and. KUSAKA, T., *et al.* ....(O) 406
pedigreed stocks of, for cultivation and metabolic studies. Dhople, A. M. and Hanks, J. H. ....(A) 137
phospholipid deacylating activities in murine leprosy bacilli. Kushiwabara, Y., *et al.* ..(A) 373
relationship between length of bacilli and log phase of growth of, in cell-free liquid medium. Sengupta, U. and Nakamura, M. ....(A) 278
role of sulfhydryls in *in vitro* growth of. Dhople, A. M. and Hanks, J. H. ....(A) 278

***Mycobacterium marinum*,**
effects of foot pad infection with . . . and *M. leprae* on natural killer cell activity as a manifestation of cell mediated immunity to local infection. Krahenbuhl, J. L. and Humphres, R. C. ....(A) 512

***Mycobacterium smegmatis*,**
arabinomannan from, an enzyme-linked immunosorbent assay, results in patients with tuberculosis and leprosy and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. ....(A) 506

***Mycobacterium ulcerans*,**
radiological abnormalities of the ileum associated with the use of clofazimine (Lamprene; B663) in the treatment of skin ulceration due to. de Bergeyck, E., *et al.* ...(A) 122

***Mycobacterium W*,**
report on the biochemical analysis of. Katoch, V. M. ....(A) 481

***Mycobacterium X*,**
from lepromata cultivated in tetradecane-DMSO medium. Kato, L. .....(C) 93

Mycolic acids,
isolation and identification of, in *M. leprae* and *M. lepraemurium*. Kusaka, T., *et al.* (O) 406
wall-bound, use of, in identification of *M. leprae*. Young, D. B. .....(A) 279

Nepal,
leprosy care activities in. .....(N) 105
ocular findings in leprosy patients in an institution. Malla, O. K., *et al.* .....(A) 366

Netherlands, The,
availability of educational materials on "leprosy in the dark skin." .....(N) 109
Dr. D. L. Leiker awarded honorary doctorate by University of Amersterdam. .....(N) 264
the Leprosy Documentation Service established. .....(N) 463
request for back issues of the IJL by Erasmus University. .....(N) 463
vacancies for doctors, Netherlands Leprosy Relief Association. .....(N) 353

Nerves,
basic function of, in leprosy patients. Brandsma, W. .....(A) 470
biopsy in Hansen's disease: fundamentals and surgical technique. Rial, R. M. L. .....(A) 474
histopathological findings of serial preparation including the total length of extremities thoracica in leprosy. Koya, G., *et al.* .....(A) 477
immunopathology of damage of, in leprosy. HILL-SMITH, I. .....(E) 223
intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with clofazimine (B663, Lamprene). McDougall, A. C. and Jones, R. L. .....(A) 362
management of nerve abscess in leprosy. Bhagat, K. P., *et al.* .....(A) 128
peripheral, do antileprosy drugs reach *M. leprae* in? Boddingius, J. and Stolz, E. ....(A) 269
radioisotope angiography with a gamma camera. Charosky, C. B., *et al.* .....(A) 470
selective loss of *M. leprae* responsiveness of circulating lymphocytes in primary neuritic leprosy. Nath, I., *et al.* .....(A) 370
simple and neurological protocol for use in the study of leprosy. Charosky, C. B. ....(A) 484
ultrastructure of, in erythema nodosum leprosy (ENL). Anthony, J., *et al.* .....(A) 273

Neuritis,
leprous, vascular changes in leprosy and its role in the pathogenesis of. Chopra, J. S., *et al.* .....(A) 471
treatment with thalidomide in steroid dependency and. Theophilus, S. .....(A) 126

Neuropathy,
electrophysiologic and histolytic studies in leprosy and some acrodystrophic neuropathies. PANDYA, S. S. and CHULAWALA, R. G. .....(O) 398
experimental leprous, degeneration and regeneration of unmyelinated fibers in. SHETTY, V. P. and ANTIA, N. H. .....(O) 324
motor, dapsone-induced optic atrophy and. Homeida, M., *et al.* .....(A) 361

New Zealand,
leprosy in Auckland. Lang, W. R. .....(A) 130
cat leprosy in, observations of. Thompson, E. J., *et al.* .....(A) 284

Nigeria,
Sixth International Conference on the Global Impacts of Applied Microbiology (GIAM VI). .....(N) 106

Norway,
International Symposium on the Epidemiology of Leprosy. .....(N) 463

Obituaries,
Andrade, Roberto Nunez. Sau, Amado. .....(Ob) 83
Yu Chia-Chun. Skinsnes, O. K.; Hu, C. K. and Ye Gan-yun. .....(Ob) 84

Pakistan,
leprosy control activities in. .....(N) 106

Papua New Guinea,
hepatitis B antigen and antibody in leprosy patients in. Ree, G. H. and Talonu, M. T. (A) 478
histology of erythema nodosum leprosum, variant forms in New Guineans and other ethnic groups. Ridley, D. S., *et al.* .....(A) 371

leprosy patients in, taking of their dapsone. Ree, G. H. and Taylor, V. E. .....(A) 126
ocular leprosy in. Ree, G. H. .....(A) 272
prevalence of ocular manifestations of leprosy in Port Moresby. Dethlefs, R. .....(A) 365

Paraguay,
Dr. W. F. Kirchheimer given plaque of appreciation. .....(N) 464

Patient compliance,
new method to monitor, under field conditions. ELISA inhibition technique for demonstration of sulfones in body fluids. Huikeshoven, H., *et al.* .....(A) 361
self-administration of dapsone by leprosy patients in Ethiopia. Ellard, G. A., *et al.* ...(A) 469
study on treatment of defaulters in leprosy at the outpatient clinic. Choi, S. R. .....(A) 365
use of dried blood to monitor, ELISA inhibition technique for the demonstration of sulfones in body fluids. Huikeshoven, H., *et al.* .....(A) 470

Phytohaemagglutinin (PHA),
-induced transformation of peripheral blood lymphocytes in leprosy patients. .....(A) 131

Philippines, The,
evaluation of a new blood test for its potential to indicate leprosy infection prior to appearance of clinical symptoms. REICH, C. V., *et al.* .....(O) 21
Leonard Wood Memorial Conference held in Manila, 9–23 January 1931, WADE, H. H. and GESHUE-TAYLOR, G. .....(E) 64
model for coordination of international donor activities with national governmental health services. Nalli, G. A. and Pearson, D. A. .....(A) 282
primary dapsone-resistant leprosy in Cebu. GUINTO, R. S., *et al.* .....(O) 427
Tenth International Congress on Tropical Medicine and Malaria .....(N) 106

Platelets,
low serotonin uptake by. SZABADOS, L., *et al.* .....(O) 42

Porphyrins,
a quantitative assay of, in leprosy patients. PAVITHARAN, P., *et al.* .....(O) 311

Pregnancy,
association of with leprosy: new cases, relapse of cured patients and deterioration in patients on treatment during, Duncan, M. E., *et al.* .....(A) 471
—, in dapsone-resistant leprosy. Duncan, M. E., *et al.* .....(A) 471

Prothionamide,
and prothionamide-S-oxide in experimental leprosy. MATSUO, Y., *et al.* .....(O) 302

Reaction(s),
conversion of, to lepromin and lepromin in patients with lepromatous leprosy by the transfer factor. Han, S. H., *et al.* .....(A) 370
histological course of, in borderline leprosy. RIDLEY, D. S. and RADIA, K. B. .....(O) 383
lepra, clofazimine (Lamprene; B663) in. Imkamp, F. M. J. H. .....(A) 470
—, a study of liver damage in leprosy patients during. Kim, D. L. .....(A) 366
liver lesions in reactional states in leprosy. Gharpuray, S. M., *et al.* .....(A) 472
Mitsuda, comparative study with integral human and armadillo lepromin in 50 patients with leprosy. Zambrano, T., *et al.* .....(A) 368
psychological, to leprosy. Behere, P. B. .....(A) 376
reversal, considerations on. Gatti, J. C., *et al.* .....(A) 471
—, management of. VAN DER MEULEN, J. and MOCK, B. .....(C) 457
reply to Dr. van der Meulen and Dr. Mock's Letter to the Editor. NAAFS, B. .....(C) 459

Renal functions,
in lepromatous leprosy. BAJAJ, A. K., *et al.* .....(O) 37
—, Sritharan, V., *et al.* .....(A) 474
histological and biochemical assessment of severity of renal amyloidosis. Bhuyan, U. N. .....(A) 486
sequential, in leprosy. Bajaj, A. K., *et al.* .....(A) 363
study of percutaneous renal biopsy in lepromatous leprosy. Gupta, S. C. .....(A) 369

Respiration,
breath holding time in leprosy. MALIK, S. K., *et al.* .....(C) 94

Rheumatoid arthritis,
effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin

and the erythrocyte sedimentation rate in rheumatoid arthritis. McConkey, B., *et al.* ....(A) 270

Rheumatoid factor,
manifestations in leprosy. Albert, D. A., *et al.* ....(A) 127

Rifampin,
asociada a levamisol. Wilkinson, F. and Liturri, M. ....(A) 127
controlled trial to compare the therapeutic effects of dapsone in combination with. Opromolla, D. V. A., *et al.* ....(O) 393
effect of single dose (1500 mg) on infectivity of patients with lepromatous leprosy. Girdhar, B. K., *et al.* ....(A) 123
estudio bioquimico de pacientes con lepra lepromatosa tratados con rifampicina y 2-mercaptopropionilglicina. Wilkinson, F. F. and Gervasi, V. ....(A) 127
interaction with other drugs. Acocella, G. ....(A) 121
once monthly with daily Lamprene® and dapsone in treatment of refactory patients with lepromatous leprosy. Paul, S. and Rose, E. T. ....(C) 342
introductory, followed by dapsone therapy, persister *M. leprae* after. Sreevasta, B. K., *et al.* ....(A) 470

Rifamycins,
comparison of antibacterial and antiimmune effects of. Kasik, J. E. and Monik, M. ....(A) 269
multivariate analysis of, against rapidly growing mycobacteria, to define an *in vitro* screening model for their activity against *M. leprae*. Pattyn, S. R. and Hebrant, F. (A) 373

Serotonin,
blood levels of, in human leprosy. Kumar, B., *et al.* ....(A) 129
antileprosy and biological antioxidant activity of. Bergel, M. ....(C) 259
uptake, by platelets, low, in leprosy, prevention of. Szabados, L., *et al.* ....(O) 42

Serum lipids,
in leprosy. Kumar, B., *et al.* ....(A) 129

Sexual dysfunction,
in leprosy. Rolston, R., *et al.* ....(O) 31
—, and female genital organs. Sharma, S. C., *et al.* ....(A) 272
—, and female reproductive organs. Sharma, S. C., *et al.* ....(A) 177

Skin,
advances in dermatology. Ratnam, A. V. ....(A) 134
adnexa in leprosy and their role in the dissemination of *M. leprae*. Kotteswaran, G., *et al.* ....(A) 132
bacterial and histopathological study of apparently normal skin in lepromatous leprosy. Katoch, V. M., *et al.* ....(A) 131
detection of mycobacterial lipids in biopsies of. Young, D. B. ....(O) 198
psoriasis and other common dermatoses in leprosy. Wahba, A., *et al.* ....(A) 131
slit . . . smears, choice of sites for study of. Kaur, S., *et al.* ....(A) 366
smears of leprosy patients, comparative study on various staining methods for *M. leprae* in. Kim, D. and Hak-Bung, K. ....(A) 370
significance of anesthetic macules in the early diagnosis of leprosy. Sun, Y. X. and Chou, H. ....(A) 367

Skinsnes, Olaf K.
personal. ....(N) 106

Social aspects,
Health Education and Social Aspects in Leprosy Work. Mehendale, M. S. ....(B) 266
image, education, and doctor-patient relationships. de Mesquita, A. P. ....(A) 485
psychodynamic side of leprosy. Chauhan, N. S. and Dhar, U. ....(A) 484
study of stigma among leprosy patients attending clinic in Gwalior. Kushwah, S. S., *et al.* ....(A) 377

Spain,
leprosy in Murcia Province, ambulatory and hospital aspects. Castro Díez, M. C., *et al.* ....(A) 281
two leprosy courses held at Fontilles. ....(N) 107

Spleen,
T cell depletion of, in patients with longstanding lepromatous leprosy. Mathias, C. ...(A) 133
The Role of the Spleen in the Immunology of Parasitic Diseases. ...(B) 118

Sulfones,
haemagglutination inhibition technique for demonstration of, in urine. Huikeshoven, H., *et al.* ...(A) 469
in body fluids, ELISA inhibition technique, for demonstration of, comparison of two ELISA methods. deWit, M., *et al.* ...(A) 468
—, —, —, a new method to monitor leprosy patient compliance under field conditions. Huikeshoven, H., *et al.* ...(A) 361
—, —, —, use of dried blood on filter paper to monitor patient compliance. Huikeshoven, H., *et al.* ...(A) 469
-induced exfoliative dermatitis and hepatitis. Lal, S. and Garg, B. R. ...(A) 125
mechanism of action of. BERGEL, M. ...(C) 89
secondary resistance to, in leprosy. Lal, S., *et al.* ...(A) 125
therapy, influence of on lepromin reaction. Ramu, G., *et al.* ...(A) 126

Switzerland,
Financial problems of tropical diseases discussed. ...(N) 263
Fourth annual report of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ...(N) 107
IMMLEP, Fifth Meeting of Scientific Working Group. ...(N) 353
IMMLEP, Sixth Meeting of Steering Committee of SWG. ...(N) 355
IMMLEP Subcommittee meeting on planning of leprosy vaccine trials. ...(N) 353
International Year of Disabled Persons (IYDP) (1981) plans made by Council of World Organizations Interested in the Handicapped (CWOIH). ...(N) 108
report of the third meeting of the Scientific Working Group on Chemotherapy of Leprosy (THELEP) of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ...(O) 431
Steering Committee of Scientific Working Group on Chemotherapy of Leprosy. ...(N) 354
Third meeting of Trans Disease Scientific Working Group on Epidemiology of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. ...(N) 108
34th World Health Assembly, address by Mrs. Indira Gandhi, Prime Minister of India. ...(N) 355
WHO experts recommend continued use of BCG vaccination against tuberculosis. ...(N) 464

Tanzania,
Scientific Conference on the Epidemiology of Leprosy held by Tanzanian Leprosy Association and Government of Tanzania. ...(N) 108

Technology(ies),
appropriate for the future. Browne, S. G. ...(A) 359

Testis,
leprous. El-Beheiry, A., *et al.* ...(A) 271

Thalidomide,
anti-inflammatory immunosuppressive . . . analogs. Piper, L. M., *et al.* ...(A) 511
immunosuppressive/anti-inflammatory . . . analogs. Hastings, R. C., *et al.* ...(A) 123
inhibition of de novo IgM antibody synthesis by, as a relevant mechanism of action in leprosy. Shannon, E. J., *et al.* ...(A) 478
structure activity relationship studies of . . . analogs as anti-inflammatory and immunosuppressive agents. Agrawal, K. C., *et al.* ...(A) 512
treatment with, in steroid dependency and neuritis. Theophilus, S. ...(A) 126

THELEP,
approach to dapsone resistant leprosy. ...(O) 421

Thiosemicarbazones,
2-acetylpyridine, antileprosy activity of. Morrison, N. E. ...(A) 510

^{2}H Thymidine,
uptake of, in *M. leprae* inoculated mouse macrophage cultures as a rapid inhibitor of bacillary viability. SATHISH, M. and NATH, I. ...(O) 187

Transfer factor,
conversion of reactions to lepromin and lepromin in patients with lepromatous leprosy by. Han, S. H., *et al.* .....(A) 370
Treatment,
adherence to drug therapy, an outpatient survey. Kritzinger, N. A. .....(A) 269
assessment of dapsone self-administration in Gudiyatham Taluk. Cates, C. J. .....(A) 360
dapsone compliance in North-east India. Davies, R. A. and Ng, Y. Y. .....(A) 361
in vitro study of the effects of home-made porcine thymosin on cellular immunity in leprosy patients—T cell responses. .....(A) 135
patient compliance with dapsone administration in leprosy. HUIKESHOVEN, H. .....(E) 228
of leprosy, a personal view. Pattyn, S. R. .....(A) 125
Tropical diseases,
The Membrane Pathobiology of Tropical Diseases. Hastings, R. C. .....(B) 117
Tuberculoid leprosy,
borderline, following BCG vaccination. STONER, G., *et al.* .....(O) 16
evolution of nasal mucosal lesions in. Mehta, L., *et al.* .....(A) 140
HLA-linked control of susceptibility to, and association of HLA-DR types. de Vries, R. R. P., *et al.* .....(A) 140
Tuberculosis,
antituberculosis activity of 6 cyclo-octylamino-5,8-quinolinequinone (CQQ). Chakraborty, A. .....(A) 468
congenital, cutaneous eruptions in. McCray, M. K. and Easterly, N. B. .....(A) 487
cutaneous, cell mediated immunity in. Sengupta, L. K., *et al.* .....(A) 488
determining the prevalence of, in populations with non-specific tuberculin sensitivity. ten Dam, H. G. .....(A) 145
domiciliary, controlled study of the effect of chemotherapy program in South India. Frimodt-Moller, J., *et al.* .....(A) 486
enzyme-linked immunosorbent assay using arabinomannan from *M. smegmatis*: results in patients with, and with leprosy, and in family contacts of leprosy patients. Miller, R. A. and Buchanan, T. M. .....(A) 506
human, antibodies to mycobacteria in. Kaplan, M. H. and Chase, M. W. .....(A) 275
immunogenetics of susceptibility to leprosy, . . . , and leishmaniasis, an epidemiological perspective. FINE, P. E. M. .....(E) 437
Leprosy-Tuberculosis Eradication. Freerksen, E. and Rosenfeld, M. .....(B) 114
present status and future prospects of chemotherapy of leprosy based on experience with treating . . . . ACOCELLA, G. .....(O) 331
pulmonary, a randomized study of two policies for managing default outpatients collecting supplies of drugs for, in a large city in South India. Krishnaswami, K. V., *et al.* .....(A) 487
—, a third study of case-finding methods for, in Kenya. Nsanzumuhire, H., *et al.* ....(A) 483
—, clinical trial of six-month and four-month regimens of chemotherapy in the treatment of. Singapore Tuberc. Service/Brit. Med. Res. Council. .....(A) 489
—, serum electrophoretic pattern in amyloidosis. Patra, S. B., *et al.* .....(A) 488
—, smear positive, immunological and clinical features of, in East Java. Kardjito, T. and Grange, J. M. .....(A) 283
soluble antigen fluorescent antibody (SAF) test in sero-diagnosis of. Bhardwaj, O. P., *et al.* .....(A) 485
specificity of the humoral immune response to soluble mycobacterial antigens in. Grange, J. M., *et al.* .....(A) 144
trial of BCG vaccines in South India for prevention of. .....(A) 145
XXV World Conference of the International Union Against Tuberculosis, Buenos Aires. .....(N) 97
WHO recommends continued use of BCG vaccination against. .....(N) 464
Turkey,
leprosy work in. .....(N) 109
Ulcer(s),
leprous neurotrophic, squamous-cell carcinoma arising in. Troy, J. L., *et al.* .....(A) 272
plantar, arteriographic pattern of, in lepromatous leprosy. Debi, B. P., *et al.* .....(A) 128

United Kingdom,
clofazimine (Lamprene, B663) in treatment of lepromatous leprosy in, a 12 year review of 31 cases. BROWNE, S. G., *et al.* .....(O) 167
history of LEPRA.....(N) 110
Manson Medal awarded to Dr. R. J. W. Rees.....(N) 110
St. George's-tide Reunion of the Order of St. Lazarus confers Silver Medal on Dr. Stanley G. Browne.....(N) 357

U.S.A.,
anniversary (75th) of American Leprosy Missions.....(N) 356
Department of Health and Human Services Honor Awards.....(N) 465
International Seminar on Leprosy & Workshop on Training.....(N) 265
Leonard Wood Memorial announces new leadership.....(N) 465
International Conference on Training and Support of Primary Health Care Workers held in Washington, D.C.....(N) 356
Inter-American Foundation, fellowships in international health.....(N) 356
Heiser Program for Research in Leprosy announces 1982 research opportunities.....(N) 357
National Council for International Health (NCIH)—1981 International Health Conference.....(N) 264
—, course entitled "New Developments in Tropical Medicine".....(N) 264
rising incidence of leprosy in. Levis, W. R. and Hedrick, J. L. .....(A) 376
third 5-year report (1975–1980) of U.S.-Japan Cooperative Medical Science Program. (N) 110

U.S.-Japan Cooperative Medical Science Program,
five-year report issued.....(N) 110
Sixteenth Joint Leprosy Conference, Bethesda, Maryland, 13–14 July 1981.....(—) 490

USSR,
International Conference on Primary Health Care. .....(N) 466

Vaccine(s),
antileprosy, searches among mycobacterial cultures for. .....(A) 139
malaria, a perspective on. Desowitz, R. S. and Miller, L. H. .....(A) 283

Vascular changes,
in leprosy, role in the pathogenesis of leprous neuritis. Chopra, J. S., *et al.* .....(A) 471
—, their responsibility in skin and nerve changes and visceral lesions. Carayon, A., *et al.* .....(A) 274

Vietnam,
message from, on 50th anniversary of ILA.....(N) 112

Vitamins,
effect of, on serial cultivation of *M. lepraemurium* in axenic liquid medium and its implication in the culture of *M. leprae*. Nakamura, M.....(A) 502

Watelet, Robert,
1980 Damien-Dutton Award. .....(N) 260

Yu Chia-Chun,
obituary. Skinsnes, O.; Hu, C. K. and Ye-Gan-yan. .....(Ob) 84

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 49, Number 1, March 1981

Original Articles — **Page**

Thomas, J., Joseph, M., Ramanujam, K., Chacko, C. J. G., and Job, C. K. Histology of the Fernandez Reaction. An Appraisal. — 1

Gupta, Subhash Kumari, Kumar, Bhushan, and Kaur, Surrinder. Aspiration Cytology of Lymph Nodes in Leprosy. — 9

Stoner, Gerald L., Belehu, Ayele, Nsibambi, John, and Warndorff, Jan. Borderline Tuberculoid Leprosy following BCG Vaccination. A Case Report. — 16

Reich, Claude V., Guinto, Ricardo S., Cellona, Roland V., Fajardo, Tranquilino T., and Madarang, Monina G. Evaluation of a New Blood Test for its Potential to Indicate Leprosy Infection Prior to the Appearance of Clinical Symptoms. — 21

Nuti, Mario, D'Amelio, Raffaele, Seminara, Rosalba, Milano, C. F., Palmisano, Lucia, and Aiuti, Fernando. Circulating Immune Complexes Detected by Clq Solid Phase Assay in Leprosy — 27

Rolston, Raj, Mathews, M., Taylor, Phyllis M., and Koshy, T. S. Hormone Profile in Lepromatous Leprosy. A Preliminary Study. — 31

Bajaj, A. K., Gupta, S. C., Sinha, S. N., Govil, D. C., Gaur, U. C., and Kumar, R. Renal Functional Status in Lepromatous Leprosy — 37

Szabados, Lenke, Launay, Jean-Marie, Mester, Madeleine, Cottenot, François, Pennec, Jean, and Mester, Làszlo. Low Serotonin Uptake by Platelets in Leprosy and a New Approach to Prevent It. — 42

Shetty, K. Taranath, Antia, Noshir H., and Krishnaswamy, P. R. Occurrence of γ-Glutamyl Transpeptidase Activity in Several Mycobacteria Including *Mycobacterium leprae* — 49

Dhople, Arvind M. and Hanks, John H. Adenosine Triphosphate Content in *Mycobacterium leprae*. A Brief Communication. — 57

Editorials

The International Leprosy Association at 50 Years. (Michel F. Lechat) — 60

Report of the Leonard Wood Memorial Conference on Leprosy Held in Manila, Phillippine Islands, January 9 to 23, 1931 — 64

Notes Concerning the Formation of the International Leprosy Association. (R. G. Cochrane) — 67

The Presidents of The International Leprosy Association. — 72

The 1980 JOURNAL—A Perspective in Leprosy. (Robert C. Hastings) — 73

The Journal is Late (Robert C. Hastings) — 82

Obituaries

Andrade, Roberto Nuñez. — 83

Yu Chia-Chun. — 84

Correspondence

A Claim for a *Mycobacterium leprae* Specific Antigen. (Morten Harboe and Otto Closs) — 85

Reply to Dr. Harboe's and Dr. Closs' Letter to the Editor. (Thomas M. Buchanan, Thomas P. Gillis, and Harlan D. Caldwell) — 88

Mechanism of Action of Sulfones. (Meny Bergel) — 89

Reply to Dr. Bergel's Letter to the Editor. (J. K. Seydel) — 90

The Fingers in Non-Lepromatous Leprosy. (C. L. Crawford) — 90

Reply to Dr. Crawford's Letter to the Editor. (A. Colin McDougall) — 91

Adherent Suppressor Cells in Polar Lepromatous Leprosy. (Pierre-Richard Ridel, Pierre Saint-André, Gerard Baquillon, Claude Ferracci, and Pierre Boucher) — 91

***Mycobacterium* X, from Lepromata Cultivated in Tetradecane-DMSO Medium.** (Laszlo Kato) — 93

Respiratory Reflexes (Breath Holding Time) in Leprosy. (Suresh K. Malik, Surrinder K. Jindal, Bhushan Kumar, and Surrinder Kaur) ---- 94
Should Indeterminate Leprosy Ever be Diagnosed? (John H. S. Pettit) ---- 95
News and Notes ---- 97
Book Reviews ---- 113
Current Literature ---- 120
Special Grantors and Sustaining Members ---- 146

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 49, Number 2, June 1981

Original Articles **Page**

Harboe, Morten, Closs, Otto, Reitan, Liv Jorun, and Draper, Philip. Demonstration of Antibodies Reacting with Different Determinants on *Mycobacterium leprae* Antigen 7. ---- 147

Sher, Ruben, Wadee, Ahmed A., Joffe, Max, Kok, Susanna H., Imkamp, Florentine M. J. H., and Simson, Ian W. The *in vivo* and *in vitro* Effects of Levamisole in Patients with Lepromatous Leprosy. ---- 159

Browne, Stanley G., Harman, Douglas J., Waudby, H., and McDougall, A. Colin. Clofazimine (Lamprene, B663) in the Treatment of Lepromatous Leprosy in the United Kingdom. A 12 Year Review of 31 Cases, 1966–1978. ---- 167

Sharma, Subhash Chander, Kumar, Bhushan, Dhall, Kamla, Kaur, Surrinder, Malhotra, Sarla, and Aikat, Meera. Leprosy and Female Reproductive Organs. ---- 177

Morrison, Norman E. and Collins, Frank M. Antimycobacterial Activity of 2-Acetylpyridine Thiosemicarbazones in Relation to Their Antileprosy Activity. ---- 180

Sathish, M. and Nath, Indira. The Uptake of ^{3}H-Thymidine in *Mycobacterium leprae* Inoculated Mouse Macrophage Cultures as a Rapid Indicator of Bacillary Viability. Factors Influencing the Specificity of the *in vitro* Assay. ---- 187

Portaels, Françoise and Pattyn, Stefaan R. Parameters Influencing the *in vitro* Growth of *Mycobacterium lepraemurium*. ---- 194

Young, Douglas B. Detection of Mycobacterial Lipids in Skin Biopsies from Leprosy Patients. ---- 198

Toman, Kurt. Bacterial Persistence in Leprosy. ---- 205

Editorials

A General Condition of the Work on the Prevention and Treatment of Leprosy in China. (Ma Haide and Ye Gan-yun) ---- 218

The Immunology of Nerve Damage in Leprosy. (Ian Hill-Smith) ---- 223

Patient Compliance with Dapsone Administration in Leprosy. (Han Huikeshoven) ---- 228

Correspondence

Antileprosy and Biological Antioxidant Activity of Serotonin. (Meny Bergel) ---- 259

News and Notes 260

Book Reviews 266

Current Literature 268

Special Grantors and Sustaining Members 285

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 49, Number 3, September 1981

Original Articles **Page**

Gillis, Thomas P., Abe, Masahide, Bullock, Ward E., Rojas-Espinosa, Oscar, Garcia-Ortigoza, Ethel, Draper, Philip, Kircheimer, Waldemar, and Buchanan, Thomas M. Comparison of 22 Species of Mycobacteria by Immunodiffusion Against an Absorbed Reference Leprosy Serum. 287

Sehgal, Shobha and Kumar, Bhushan. Circulating and Tissue Immune Complexes in Leprosy. 294

Matsuo, Yoshiyasu, Tatsukawa, Hiroshi, Murray, John F., Jr., and Peters, John H. Prothionamide and Prothionamide-S-Oxide in Experimental Leprosy. 302

Sritharan, V., Bharadwaj, V. P., Venkatesan, K., and Girdhar, B. K. Dapsone Induced Hypohaptoglobinemia in Lepromatous Leprosy Patients. 307

Pavithran, P., Handa, F., and Sidhu, K. S. A Quantitative Assay of Porphyrins in Leprosy Patients. A Spectrophotometric Study. 311

Mascaro, Jose M., Ferrando, Juan, and Gratacos, Rosa. Lepromatous Leprosy Clinically Localized to One-Half of the Face. Report of a Case. 315

Fieldsteel, A. Howard, Sato, Norio, and Colston, M. Joseph. Relationship Between T-Cell Population in Neonatally Thymectomized Lewis Rats and Susceptibility to Infection with *Mycobacterium leprae*. 317

Shetty, V. P. and Antia, N. H. Degeneration and Regeneration of Unmyelinated Fibers in Experimental Leprous Neuropathy. 324

Editorials

Some Thoughts on the Present Status and Future Prospects of Chemotherapy of Leprosy Based on Experience with Treating Tuberculosis. (G. Acocella) 331

Correspondence

Decline of Leprosy in Mainland China. (Olaf K. Skinsnes) 341

Rifampin 1200 mg Once Monthly Together With Daily Lamprene® and Dapsone in Treatment of Refactory Patients with Lepromatous Leprosy. (Bro. Sannyasi Paul and Elizar T. Rose) 342

Lipids and Lipoprotein Profiles in Leprosy. (C. Sita Devi, Y. Mohan Kumar, M. Patrudu, C. R. R. M. Reddy, and B. Narasimha Rao) 344

Nine-Banded Armadillos in Captivity: Prevention of Losses Due to Parasitic Diseases. Some Remarks on Mycobacteria-free Maintenance. (J. M. Kazda) 345

News and Notes 347

Book Reviews 358

Current Literature 359

Statement of Financial Condition 379

Special Grantors and Sustaining Members 382

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 49, Number 4, December 1981

Original Articles **Page**

Ridley, Dennis S. and Radia, K. B. The Histological Course of Reactions in Borderline Leprosy and Their Outcome. 383

Opromolla, Diltor Vladimir Araujo, Tonello, Claudio Joaquim Sampaio, McDougall, A. Colin, and Yawalkar, S. J. A Controlled Trial to Compare the Therapeutic Effects of Dapsone in Combination with Daily or Once-Monthly Rifampin in Patients with Lepromatous Leprosy. 393

Pandya, S. S. and Chulawala, R. G. Electrophysiologic and Histologic Studies in Leprosy and Some Acrodystrophic Neuropathies. 398

Kusaka, Takashi, Kohsaka, Kenji, Fukunishi, Yukiko, and Akimori, Hiromi. Isolation and Identification of Mycolic Acids in *Mycobacterium leprae* and *Mycobacterium lepraemurium*. 406

Pearson, John M. H. The Problem of Dapsone-Resistant Leprosy. 417

Dapsone-Resistant Leprosy—The THELEP Approach. 421

Guinto, Ricardo S., Cellona, R. V., Fajardo, T. T., and de la Cruz, E. C. Primary Dapsone-Resistant Leprosy in Cebu, Philippines. 427

Report of the Third Meeting of the Scientific Working Group on Chemotherapy of Leprosy (THELEP) of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, 20–22 October 1980. 431

Editorials

Immunogenetics of Susceptibility to Leprosy, Tuberculosis, and Leishmaniasis. An Epidemiological Perspective. (Paul E. M. Fine) 437

Correspondence

***In Vitro* Stimulation of Human Lymphocytes With Mycobacterial Antigens.** (E. P. Wright and Radhika Rangarajan) 455

DDS 100 mg Daily, the Cornerstone in the Management of Reversal Reaction. (J. van der Meulen and B. Mock) 457

Reply to Dr. van der Meulen and Dr. Mock's Letter to the Editor. (Ben Naafs) 459

News and Notes 460

Reviewers 467

Current Literature 468

U.S.–Japan Cooperative Medical Science Program, Sixteenth Joint Leprosy Research Conference, Bethesda, Maryland, 1981. 490

International Leprosy Association Organization and Membership, 1981. 520

Special Grantors and Sustaining Members. 533

Index, Volume 49 534

Statement of Ownership, Management, and Circulation 563